document type sequence filename description text html head title title head body bgcolor white style margin margin bottom font size font family time roman align right exhibit style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size font family time roman align center collaborative research development style margin margin bottom font size font family time roman align center commercialization license agreement style margin margin bottom font size font family time roman align center between style margin margin bottom font size font family time roman align center proteostasis therapeutic style margin margin bottom font size font family time roman align center style margin margin bottom font size font family time roman align center biogen idec venture style margin margin bottom font size font family time roman align center december nbsp style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center table content style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid page valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman definition valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman research program governance valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman development valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman commercialization valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman development commercialization option valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman payment valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman ownership intellectual property license valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman patent filing prosecution maintenance enforcement valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman confidential information publicity publication valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman representation warranty valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman indemnification insurance valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman term termination valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman miscellaneous valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center collaborative research development commercialization style margin margin bottom font size font family time roman align center license agreement style margin margin bottom text indent font size font family time roman this collaborative research development commercialization license agreement this agreement entered into december nbsp effective date between proteostasis therapeutic delaware corporation having principal place business technology square fourth floor cambridge biogen idec venture massachusetts corporation having principal place business cambridge center cambridge biogen idec each biogen idec sometimes referred individually herein party collectively party style margin margin bottom text indent font size font family time roman whereas expertise proprietary technical information know relating application protein folding trafficking clearance based small molecule therapeutic treatment disease committed research development therapeutic method product treatment disease style margin margin bottom text indent font size font family time roman whereas owns control certain proprietary right related target defined below filed licensed patent application covering such target well certain thereof style margin margin bottom text indent font size font family time roman whereas biogen idec engaged research development production marketing sale therapeutic interested development commercialization therapeutic targeting toxic protein aggregation style margin margin bottom text indent font size font family time roman whereas party wish collaborate research development commercialization licensed product defined below that modulate target term forth this agreement style margin margin bottom text indent font size font family time roman therefore consideration mutual covenant contained herein other good valuable consideration party hereto intending legally bound hereby agree follows style margin margin bottom font size font family time roman align center definition style margin margin bottom font size font family time roman whenever used this agreement with initial capital letter term defined this section nbsp will have meaning specified style margin margin bottom text indent font size font family time roman adverse event mean untoward medical occurrence human clinical trial subject patient administered development compound licensed product style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman whether considered related such development compound licensed product including undesirable sign including abnormal laboratory finding clinical concern symptom disease associated with such development compound licensed product style margin margin bottom text indent font size font family time roman affiliate mean with respect party other person controlling controlled under common control with such party purpose this section nbsp term control including with correlative meaning term controlled under common control with used with respect person mean ownership directly indirectly more than fifty percent nbsp voting stock other ownership interest such person possession directly indirectly power direct cause direction affair management policy such person whether through ownership voting security contract trustee personal representative executor otherwise party acknowledge that case certain entity organized under certain country outside united state maximum percentage ownership permitted foreign investor than fifty percent that such case such lower percentage will substituted preceding sentence provided that such foreign investor power direct affair management policy such entity style margin margin bottom text indent font size font family time roman annual sale mean with respect calendar year aggregate amount sale country such calendar year style margin margin bottom text indent font size font family time roman biogen idec collaboration technology mean collectively biogen idec collaboration know biogen idec collaboration patent right style margin margin bottom text indent font size font family time roman biogen idec know mean style margin margin bottom text indent font size font family time roman know whether patentable that nbsp controlled biogen idec affiliate effective date nbsp necessary useful conduct research program develop commercialize compound lead compound development compound backup compound licensed product biogen idec background know style margin margin bottom text indent font size font family time roman know whether patentable that made created course performing research development commercialization activity under collaboration solely biogen idec affiliate their respective representative biogen idec collaboration know style margin margin bottom text indent font size font family time roman biogen idec interest joint collaboration know style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman biogen idec patent right mean style margin margin bottom text indent font size font family time roman patent right form that controlled biogen idec affiliate effective date that cover compound lead compound development compound backup compound licensed product including composition matter thereof method making compound lead compound development compound backup compound licensed product method using compound lead compound development compound backup compound licensed product method assay screening compound that modulates target otherwise necessary useful conduct research program develop commercialize development compound licensed biogen idec background patent right style margin margin bottom text indent font size font family time roman patent right form that controlled biogen idec affiliate that cover invention included biogen idec collaboration know biogen idec collaboration patent right style margin margin bottom text indent font size font family time roman biogen idec interest joint collaboration patent right style margin margin bottom text indent font size font family time roman biogen idec proprietary compound mean compound that originates from library biogen idec affiliate third party with respect which biogen idec control patent right covering such compound whether composition matter method other than patent right that joint collaboration technology style margin margin bottom text indent font size font family time roman biogen idec technology mean collectively biogen idec know biogen idec patent right style margin margin bottom text indent font size font family time roman budget mean budget that part research plan style margin margin bottom text indent font size font family time roman business mean other than saturday sunday which banking institution boston massachusetts open business style margin margin bottom text indent font size font family time roman calendar quarter mean period beginning effective date ending last calendar quarter which effective date fall thereafter each successive period three nbsp consecutive calendar month ending march nbsp nbsp june nbsp nbsp september nbsp december nbsp provided that final calendar quarter will last term style margin margin bottom text indent font size font family time roman calendar year mean period beginning effective date ending december nbsp calendar year which effective date fall thereafter each successive period twelve nbsp month commencing january nbsp ending december nbsp provided that final calendar year will last term style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman change control mean following nbsp merger consolidation into with person that affiliate unaffiliated acquiror transfer outstanding voting equity security more unaffiliated acquirors single transaction series transaction which either case member stockholder shareholder immediately prior thereto aggregate longer directly indirectly beneficially legally least fifty percent nbsp voting power successor entity issued outstanding voting equity security after such transaction transaction nbsp third party operating entity that directly engaged pharmaceutical biotechnology similar life science business including their venture capital other affiliate including single third party third party concert together group purpose acquiring share order direct affair divest those portion which reasonably necessary conduct activity under this agreement becoming beneficial owner fifty percent nbsp more combined voting power outstanding security nbsp sale other disposition third party substantially asset business style margin margin bottom text indent font size font family time roman collaboration mean alliance biogen idec established pursuant this agreement purpose researching developing commercializing licensed product field territory style margin margin bottom text indent font size font family time roman collaborator mean investigator university profit research organization with which party contract conduct research development commercialization activity related collaboration style margin margin bottom text indent font size font family time roman commercialization commercialize mean activity directed offering sale sale licensed product applicable country including nbsp conducting post regulatory approval activity including nbsp activity directed marketing promoting detailing distributing manufacturing importing selling offering sell such licensed product nbsp study reasonably required increase market potential licensed product study provide improved formulation licensed product delivery such licensed product each country nbsp interacting with regulatory authority regarding foregoing nbsp seeking pricing approval reimbursement approval such licensed product when used verb commercialize commercializing mean engage commercialization commercialized corresponding meaning style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman commercially reasonable effort mean relation obligation assumed party under this agreement effort resource comparable those which such party generally accomplish equivalent task used relation development registration manufacture marketing distribution sale product effort used such party relation pipeline product similar market potential profit potential similar stage development product life resulting from research effort based condition then prevailing taking into account without limitation issue safety efficacy regulatory authority approved labeling product profile competitiveness alternative product marketplace likely timing product entry into market patent other proprietary position likelihood regulatory approval other relevant scientific technical commercial factor style margin margin bottom text indent font size font family time roman compound mean small molecule that style margin margin bottom text indent font size font family time roman synthesized assayed against target third party acting behalf prior effective date nbsp synthesized assayed intentionally against target biogen idec third party acting behalf biogen idec prior effective date nbsp synthesized assayed against target behalf party course performing activity under research program small molecule synthesized assayed described nbsp nbsp above clarity assaying described nbsp nbsp above will exclude style margin margin bottom text indent font size font family time roman modulates activity target primary intended mechanism action therapeutic effect style margin margin bottom text indent font size font family time roman style font size vertical align bottom such chemical entity target vitro assay than equal with selectivity against style margin margin bottom font size font family time roman compound synthesized assayed against target biogen idec third party acting behalf either party prior effective date will forth side letter agreement entered into party substantially concurrently with this agreement style margin margin bottom text indent font size font family time roman compound related patent right mean licensed patent that include claim covering licensed product lead compound development compound back compound their treating indication within field style margin margin bottom text indent font size font family time roman confidential information mean nbsp with respect tangible embodiment licensed technology nbsp with respect biogen idec tangible embodiment biogen idec technology nbsp with respect each party information invention know material that disclosed provided behalf such party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman disclosing party other party receiving party receiving party employee consultant collaborator affiliate sublicensees pursuant this agreement whether specifically marked designated disclosing party confidential purpose clarity disclosed term this agreement will deemed confidential information both party style margin margin bottom text indent font size font family time roman control controlled mean with respect intellectual property right possession party affiliate such party applicable right grant license sublicense such intellectual property right provided herein without violating term agreement arrangement with infringing patent right misappropriating proprietary trade secret information third party without violating applicable regulation notwithstanding foregoing party affiliate party applicable will deemed control intellectual property right solely virtue license grant forth this agreement style margin margin bottom text indent font size font family time roman cover cover covered mean with respect particular product issue relevant patent right that license granted party under claim included such patent right manufacture sale offer sale importation such party product issue would infringe such claim case patent right that patent application would infringe claim such patent application were issue patent particular country country style margin margin bottom text indent font size font family time roman data protection mean with respect particular sole licensed product legal regulatory prohibition particular country sale drug that contains same compound such sole licensed product claimed equivalent such sole licensed product generic product including without limitation barring reliance upon clinical data with respect such sole licensed product gain regulatory approval generic product requiring more than mere equivalency data support regulatory approval generic product style margin margin bottom text indent font size font family time roman development develop mean with respect development compound back compound licensed product research preclinical clinical regulatory activity including grant regulatory approval such development compound back compound licensed product including human clinical trial conducted after regulatory approval licensed product particular indication whether such indication first indication such licensed product subsequent indication when used verb developing mean engage development developed corresponding meaning style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman development compound mean lead compound that meet criterion forth exhibit this agreement development compound criterion that designated biogen idec biogen idec sole discretion further development accordance with section avoidance doubt development compound includes primary development compound style margin margin bottom text indent font size font family time roman distributor mean profit third party that distributor licensed product anywhere world resale provided that nbsp such third party affiliate biogen idec affiliate sublicensee biogen idec nbsp such third party been granted sublicense develop have developed make have made such licensed product except extent that such sublicense necessary such third party nbsp perform final packaging such licensed product nbsp conduct clinical trial such licensed product support regulatory approval thereof such third party territory purpose this defined term distributor only sublicense used this section nbsp only includes nbsp option other right negotiate receive sublicense nbsp standstill similar obligation toward third party grant sublicense option obtain sublicense other third party case excluding sublicense such other right enumerated clause nbsp nbsp that limited right market distribute sell support licensed product style margin margin bottom text indent font size font family time roman mean european medicine agency successor agency authority thereto style margin margin bottom text indent font size font family time roman excluded field mean diagnosis treatment prevention human animal avoidance doubt excluded field will include diagnosis treatment prevention disease human animal nbsp that have been tested under research plan nbsp which compound been advanced into clinical development biogen idec affiliate sublicensees prior commencement research development activity affiliate licensee sublicensees following research term requested writing party will consider revising excluded field include certain additional disease human animal based finding outcome research plan style margin margin bottom text indent font size font family time roman mean united state food drug administration successor agency authority thereto style margin margin bottom text indent font size font family time roman fdca mean united state federal food drug cosmetic amended style margin margin bottom text indent font size font family time roman field mean diagnosis treatment prevention disease human animal style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman first commercial sale mean date first sale biogen idec sublicensee their affiliate licensed product third party consumption such licensed product following receipt required regulatory approval country which such licensed product sold excluding however sale other distribution cost than cost discovery research activity clinical study compassionate named patient style margin margin bottom text indent font size font family time roman force majeure mean occurrence beyond reasonable control party that prevents substantially interferes with performance such party obligation hereunder reason flood fire explosion earthquake strike lockout labor dispute casualty accident revolution civil commotion terrorism blockage embargo injunction order proclamation regulation ordinance demand requirement government subdivision authority representative such government style margin margin bottom text indent font size font family time roman mean total week hour year scientific work performed employee contractor agent party having appropriate relevant expertise conduct such activity directly related collaboration style margin margin bottom text indent font size font family time roman cost equal number relevant ftes multiplied applicable rate style margin margin bottom text indent font size font family time roman rate mean will increase annually with first such increase commencing january nbsp reflect change over preceding twelve nbsp month which data then available consumer price index urban consumer city average item published united state department labor bureau statistic style margin margin bottom text indent font size font family time roman vivo target validation mean demonstration experiment animal model agreed biogen idec including limited that mediate inhibition target nbsp least biogen idec will have right sole discretion waive lower applicable percentage requirement each these nbsp another specific percentage mutually agreed between party nbsp pharmacological above experimental system mutually agreed between party style margin margin bottom text indent font size font family time roman indication mean each separate distinct disease illness condition interruption cessation disorder particular bodily function system tissue type organ sign symptom such item condition regardless severity frequency route treatment dosage strength patient class style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman information mean collectively proprietary information know data analysis result whatsoever form idea concept including information data forth investigator brochure regulatory filing regulatory approval business financial information information relating method technique procedure design plan specification apparatus equipment expression synthesis manufacture stability formulation dosage form pharmacology toxicology pharmacokinetics clinical efficacy safety style margin margin bottom text indent font size font family time roman infringed reasonably necessary mean intellectual property right whether issued pending that nbsp cover claim with respect pending right would cover claim issued research development manufacture commercialization sale importation exportation sole licensed product applicable jurisdiction nbsp fall within clause nbsp this section nbsp where lack right practice such intellectual property right would effectively prevent research development manufacture commercialization sale importation exportation sole licensed product because such intellectual property right cover claim with respect pending right would cover claim issued right that necessary research development manufacture commercialization sale importation exportation sole licensed product applicable jurisdiction such purpose illustration only intellectual property right that cover claim delivery formulation manufacturing other technology that would necessary commercialize sole licensed product applicable jurisdiction style margin margin bottom text indent font size font family time roman intellectual property right mean collectively know patent right style margin margin bottom text indent font size font family time roman invention mean invention discovery improvement process technique useful process method manufacture composition matter material whether patentable that conceived first reduced practice either party jointly both party after effective date during term conduct research development commercialization licensed product style margin margin bottom text indent font size font family time roman investigator brochure mean compilation preclinical clinical data with respect investigational drug that proposed filing with regulatory authority used provide information clinical investigator regulatory authority style margin margin bottom text indent font size font family time roman jnda mean drug application submitted ministry health labor welfare obtain regulatory approval marketing licensed product japan style margin margin bottom text indent font size font family time roman joint collaboration know mean nbsp know whether patentable made created course performing activity under collaboration jointly nbsp affiliate their respective representative nbsp biogen idec affiliate their respective representative style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman joint collaboration patent right mean patent right that cover invention included joint collaboration know style margin margin bottom text indent font size font family time roman joint collaboration technology mean collectively joint collaboration know joint collaboration patent right style margin margin bottom text indent font size font family time roman know mean collectively invention discovery improvement trade secret proprietary information method whether patentable including without limitation example method manufacture structural functional information pertaining material compound composition matter data formulation process technique know result including negative result style margin margin bottom text indent font size font family time roman lead compound mean compound that meet criterion forth exhibit this agreement lead compound criterion that designated biogen idec biogen idec sole discretion lead compound accordance with section nbsp style margin margin bottom text indent font size font family time roman licensed biogen idec proprietary compound mean biogen idec proprietary compound that were time prior termination this agreement lead compound back compound contained licensed product product containing same style margin margin bottom text indent font size font family time roman licensed know mean style margin margin bottom text indent font size font family time roman know whether patentable that nbsp controlled affiliate effective date nbsp necessary useful conduct research program develop commercialize compound lead compound development compound back compound licensed product background know style margin margin bottom text indent font size font family time roman know whether patentable that made created course performing research development commercialization activity under collaboration solely affiliate their respective representative collaboration know style margin margin bottom text indent font size font family time roman interest joint collaboration know style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style font size margin margin bottom nbsp style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman licensed patent mean style margin margin bottom text indent font size font family time roman patent right form that controlled affiliate effective date that cover compound lead compound development compound backup compound licensed product including composition matter thereof method making compound lead compound development compound backup compound licensed product method using compound lead compound development compound backup compound licensed product method assay screening compound that modulates target otherwise necessary useful conduct research program develop commercialize lead compound development compound backup compound licensed product background patent right style margin margin bottom text indent font size font family time roman patent right form that controlled solely affiliate that cover invention included collaboration know collaboration patent right style margin margin bottom text indent font size font family time roman interest joint collaboration patent right style margin margin bottom text indent font size font family time roman licensed product mean product field that contains consists development compound active ingredient style margin margin bottom text indent font size font family time roman licensed technology mean collectively licensed know licensed patent style margin margin bottom text indent font size font family time roman mean marketing authorization application submitted pursuant centralized approval procedure obtain european commission approval marketing licensed product european union successor application procedure required sell licensed product european union style margin margin bottom text indent font size font family time roman major market country mean following country style margin margin bottom text indent font size font family time roman material mean tangible chemical biological physical material style margin margin bottom text indent font size font family time roman mean drug application biologics license application equivalent filing that filed with regulatory authority that necessary approval market sell pharmaceutical licensed product country country which such regulatory authority jurisdiction style margin margin bottom text indent font size font family time roman sale mean with respect each country world gross amount sale licensed product such country biogen idec sublicensees their respective affiliate each case invoicing entity third party including limited distributor following deduction each case nbsp extent already style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman deducted excluded from gross amount invoiced nbsp without duplication nbsp where applicable with respect gross amount invoiced licensed product nbsp incurred ordinary course business type amount consistent with good industry practice determined accordance with recorded revenue under united state generally accepted accounting principle style margin margin bottom text indent font size font family time roman sale return allowance other adjustment actually paid granted taken accrued licensed product including trade quantity prompt cash discount adjustment granted account price adjustment billing error style margin margin bottom text indent font size font family time roman credit allowance given made taken rejection return previously sold licensed product rebate retroactive price reduction including medicare medicaid managed care similar type rebate chargebacks style margin margin bottom text indent font size font family time roman duty other governmental charge levied measured billing amount licensed product adjusted rebate refund which avoidance doubt shall include duty other charge imposed measured income however denominated franchise branch profit similar style margin margin bottom text indent font size font family time roman custom excise duty sale consumption value added other except income adjusted rebate refund style margin margin bottom text indent font size font family time roman pharmaceutical excise such those imposed united state patient protection affordable care nbsp other comparable style margin margin bottom text indent font size font family time roman charge freight insurance paid that directly related distribution licensed product style margin margin bottom text indent font size font family time roman credit allowance given made taken wastage replacement licensed product style margin margin bottom text indent font size font family time roman viii wholesaler distributor administration paid that directly related distribution licensed product style margin margin bottom text indent font size font family time roman other similar customary deduction taken ordinary course business accordance with united state generally accepted accounting principle that directly related distribution licensed product style margin margin bottom text indent font size font family time roman sale shall determined accordance with united state generally accepted accounting principle sale shall imputed transfer licensed product style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman clinical trial bona fide charitable purpose compassionate indigent patient program reasonable quantity free licensed product sample such transfer exempted transfer exempted transfer shall made manner consistent with invoicing entity practice with respect licensed product prior effective date style margin margin bottom text indent font size font family time roman notwithstanding foregoing event licensed product sold component combination product defined below country world calendar quarter such country both licensed product other component also sold separately from each other during such calendar quarter then sale shall calculated multiplying sale combination product such country during such calendar quarter calculated applying criterion forth above applied sale such combination product such country fraction where average sale unit sold licensed product when sold separately such country during such calendar quarter calculated determining sale licensed product such country during such calendar quarter accordance with criterion forth above dividing such sale number unit licensed product sold such country during such calendar quarter average sale unit sold other active component included combination product when sold separately such country during such calendar quarter calculated determining sale such other active component such country during such calendar quarter applying criterion forth above applied sale such other active component dividing such sale number unit such other active component sold such country during such calendar quarter event licensed product sold component combination product defined below country world calendar quarter such country licensed product sold separately such calendar quarter other component then sale shall calculated multiplying sale combination product such country during such calendar quarter calculated applying criterion forth above applied sale such combination product such country fraction where average sale unit sold licensed product when sold separately such country during such calendar quarter calculated determining sale licensed product such country during such calendar quarter accordance with criterion forth above dividing such sale number unit licensed product sold such country during such calendar quarter average sale unit sold combination product during such calendar quarter calculated determining sale combination product such country during such calendar quarter applying criterion forth above applied sale combination product whole dividing such sale number unit combination product sold such country during such calendar quarter purpose calculating average sale unit sold licensed product other active component combination product accordance with above described equation deduction described clause nbsp through nbsp above that apply such style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman combination product shall allocated among sale licensed product sale other active component included such combination product follows nbsp deduction that attributable solely licensed product other active component shall allocated solely sale licensed product such other active component applicable nbsp other deduction shall allocated among sale licensed product sale other active component proportion party agreed upon reasonable good faith estimate fair market value licensed product other active component event that separate sale licensed product included combination product made invoicing entity during calendar quarter which such combination product sold country average sale unit sold above described equation shall replaced with party agreed upon reasonable good faith estimate fair market value licensed product each other active component included such combination product purpose this section nbsp combination product mean nbsp single product finished form containing active ingredient both nbsp licensed product nbsp more other pharmaceutically active compound substance nbsp sale licensed product with another product single invoice price nbsp sale licensed product part bundle with other product service where licensed product such other product service sold single invoice price where discount rebate other amount that reduces price licensed product provided exchange otherwise conditioned upon purchase such other product service extent described clause nbsp style margin margin bottom text indent font size font family time roman transfer licensed product between invoicing entity affiliate such invoicing entity purpose resale such affiliate sale will equal fair market value licensed product transferred assuming length transaction made ordinary course business event that invoicing entity receives cash consideration licensed product case transaction length with affiliate invoicing entity sale will calculated based fair market value such consideration transaction assuming length transaction made ordinary course business sale licensed product invoicing entity affiliate sublicensee resale such affiliate sublicensee will deemed sale instead sale will determined based gross amount billed invoiced such affiliate sublicensee upon resale such licensed product third party purchaser that affiliate sublicensee avoidance doubt nbsp sale shall calculated based transfer distributor transfer from distributor user customer nbsp nothing this paragraph anywhere else this section nbsp shall construed include exempted transfer calculation determination sale style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman notwithstanding anything this agreement contrary invoicing entity shall shall cause affiliate take action omit take action primary purpose reducing amount payment otherwise style margin margin bottom text indent font size font family time roman patent right mean right interest issued patent pending patent application which purpose this agreement include certificate invention application certificate invention priority right country region including provisional application substitution continuation continuation part division renewal letter patent granted thereon reissue examination extension thereof including patent term extension supplemental protection certificate foreign counterpart foregoing style margin margin bottom text indent font size font family time roman person mean individual sole proprietorship partnership limited partnership limited liability partnership corporation limited liability company business trust joint stock company trust incorporated association joint venture similar entity organization including government political subdivision department agency government style margin margin bottom text indent font size font family time roman phase trial mean licensed product phase study defined section nbsp volume code federal regulation equivalent trial thereto outside united state style margin margin bottom text indent font size font family time roman phase trial mean licensed product phase study including phase phase study defined equivalent trial thereto outside united state style margin margin bottom text indent font size font family time roman phase trial mean licensed product phase study defined equivalent trial thereto outside united state style margin margin bottom text indent font size font family time roman program sale mean nbsp sale license unaffiliated acquiror substantially asset that relate specific licensed product licensed product that nbsp constitute change control style margin margin bottom text indent font size font family time roman collaboration technology mean collectively collaboration know collaboration patent right style margin margin bottom text indent font size font family time roman qualified service provider mean third party vendor service provider engaged provide good service with respect activity related collaboration service basis behalf party hereunder enters into agreement that consistent with term this agreement without limiting generality foregoing such agreement must contain assignment invention deliverable other result style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman work done under such agreement contracting party provision protecting confidentiality information that least stringent term contained section nbsp this agreement style margin margin bottom text indent font size font family time roman regulatory approval mean with respect country region territory approval license registration authorization applicable regulatory authority such country region necessary marketing sale licensed product such country region including pricing reimbursement approval legally practically required market sell licensed product such country style margin margin bottom text indent font size font family time roman regulatory authority mean with respect country outside regulatory agency ministry department other governmental body having authority such country substantially equivalent authority regulate development manufacture marketing promotion sale pharmaceutical product style margin margin bottom text indent font size font family time roman regulatory filing mean collectively nbsp inds ndas maas jndas blas establishment license application drug master file application designation orphan licensed product under orphan drug fast track status under section nbsp fdca special protocol assessment under section nbsp nbsp fdca breakthrough therapy designation under section nbsp fdasia other similar filing including without limitation counterpart foregoing country region territory nbsp supplement amendment foregoing nbsp data other information contained correspondence relating foregoing style margin margin bottom text indent font size font family time roman research plan mean mutually agreed research plan budget research program initial research plan attached this agreement exhibit style margin margin bottom text indent font size font family time roman research program mean research activity conducted party under research plan with principal goal nbsp discovering compound nbsp characterizing optimizing supporting progression such compound lead compound into clinical development development compound including identification validation biomarkers other measure pharmacodynamic outcome style margin margin bottom text indent font size font family time roman research term mean period beginning effective date unless terminated earlier accordance with section nbsp ending fourth style font size vertical align nbsp anniversary effective date style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman royalty free product mean small molecule other than biogen idec proprietary compound that time definition compound under this agreement that intended primarily modulate target product containing same style margin margin bottom text indent font size font family time roman royalty term mean with respect each sole licensed product each country territory period beginning date first commercial sale such licensed product such country ending later nbsp expiration last valid claim covering such sole licensed product such country nbsp nbsp year following first commercial sale such sole licensed product such country nbsp expiration data protection such sole licensed product such country style margin margin bottom text indent font size font family time roman small molecule mean chemical entity that molecular weight that than dalton style margin margin bottom text indent font size font family time roman sublicensee mean nbsp with respect biogen idec person other than biogen idec affiliate distributor biogen idec which biogen idec grant license sublicense similar right under licensed technology research develop make import offer sale sell development compound back compound licensed product nbsp with respect either nbsp person other than affiliate distributor which grant license sublicense similar right under biogen idec technology research develop make import offer sale sell discontinued collaboration compound product containing discontinued collaboration compound nbsp qualified service provider which grant license sublicense similar right under biogen idec technology style margin margin bottom text indent font size font family time roman target mean ubiquitinating enzyme known style margin margin bottom text indent font size font family time roman territory mean country territory world style margin margin bottom text indent font size font family time roman third party mean person entity corporation other than party their affiliate style margin margin bottom text indent font size font family time roman valid claim mean nbsp claim issued unexpired patent within patent right that been nbsp held permanently revoked unenforceable unpatentable invalid decision court governmental body competent jurisdiction unappealable unappealed within time allowed appeal nbsp cancelled disclaimed denied otherwise held invalid unenforceable through reissue reexamination disclaimer derivation opposition otherwise nbsp abandoned nbsp permanently lost through interference derivation inter partes reexamination parte reexamination post grant review opposition proceeding without right appeal review nbsp pending claim pending patent application within style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman patent right that nbsp been asserted continues prosecuted good faith been cancelled withdrawn abandoned without being refiled another application applicable jurisdiction nbsp been abandoned finally rejected without possibility appeal refiling provided that patent application pending more than nbsp year from date issuance first patent office action merit regarding patentability such claim relevant patent office country territory which such claim pending excluding time during which such application interference derivation opposition similar proceeding decision examiner with respect such application being appealed shall considered valid claim purpose this agreement from after such nbsp year date unless until patent issue from such patent application style margin margin bottom text indent font size font family time roman additional definition addition each following definition will have respective meaning forth section this agreement indicated below style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman definition valign bottom nbsp nbsp valign bottom align center style border bottom solid section style font family time roman font size valign style margin left text indent font size font family time roman abandoning party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman action valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman additional intellectual property valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman agreement valign bottom nbsp nbsp valign bottom nowrap recital style font family time roman font size valign style margin left text indent font size font family time roman assuming party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman audited party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman auditing party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman back compound valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman bankrupt party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman bankruptcy code valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman biogen idec valign bottom nbsp nbsp valign bottom nowrap recital style font family time roman font size valign style margin left text indent font size font family time roman biogen idec background know valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman biogen idec background patent right valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman biogen idec collaboration know valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman biogen idec collaboration patent right valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman competitor valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman commercialization option valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman commercialized product valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman developed licensed product valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman development compound valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman development option valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman development plan valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman commercialization plan valign bottom nbsp nbsp valign bottom nowrap table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman definition valign bottom nbsp nbsp valign bottom align center style border bottom solid section style font family time roman font size valign style margin left text indent font size font family time roman combination product valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman development commercialization license valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman development compound criterion valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman development compound milestone payment valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman development milestone event valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman development milestone payment valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman disclosing party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman discontinued collaboration compound valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman effective date valign bottom nbsp nbsp valign bottom nowrap recital style font family time roman font size valign style margin left text indent font size font family time roman forgone grant amount valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman forgone grant calendar quarter valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman generic product valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman exempted transfer valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman harvard valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman harvard development milestone valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman harvard license valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman harvard patent right valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman indemnitee valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman independent expert valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman infringement valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman infringement notice valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman invoicing party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman lead compound criterion valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman negotiation period valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman bankrupt party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman operational deadlock valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman party party valign bottom nbsp nbsp valign bottom nowrap recital style font family time roman font size valign style margin left text indent font size font family time roman patent coordinator valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman phase development termination option valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman post research term development support activity valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman primary development compound valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nowrap recital style font family time roman font size valign style margin left text indent font size font family time roman background know valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman background patent right valign bottom nbsp nbsp valign bottom nowrap table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman definition valign bottom nbsp nbsp valign bottom align center style border bottom solid section style font family time roman font size valign style margin left text indent font size font family time roman collaboration know valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman collaboration patent right valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman subsidiary valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman publishing party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman receiving party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman reconciliation payment valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman research license valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman reviewing party valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman sale notice valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman sbir grant valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman sole commercialization plan valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman sole development compound valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman sole development plan valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman sole licensed product valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman term valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman third party agreement valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman total quarterly expense valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman unaffiliated acquiror valign bottom nbsp nbsp valign bottom nowrap style font family time roman font size valign style margin left text indent font size font family time roman upfront valign bottom nbsp nbsp valign bottom nowrap table style margin margin bottom font size font family time roman align center research program governance style margin margin bottom text indent font size font family time roman conduct research program during research term party will collaborate conduct research program accordance with research plan budget each party will exercise commercially reasonable effort conduct their respective obligation under research plan with respect each compound that subject research program style margin margin bottom text indent font size font family time roman provision know material each party will provide other party nbsp such know controlled such party nbsp such material possessed such party with right provide hereunder each case required under research plan style margin margin bottom text indent font size font family time roman governance style margin margin bottom text indent font size font family time roman establishment promptly after execution this agreement party will establish joint research committee comprised equal number representative from senior science management each party review oversee conduct research program style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman responsibility will style margin margin bottom text indent font size font family time roman coordinate research program including assigning activity performed each party under research plan style margin margin bottom text indent font size font family time roman discus designation compound lead compound lead compound development compound style margin margin bottom text indent font size font family time roman establish monitor progress against objective research program style margin margin bottom text indent font size font family time roman update approve change research plan budget least annually style margin margin bottom text indent font size font family time roman exchange review scientific information data relating activity being conducted under research program style margin margin bottom text indent font size font family time roman make such other decision expressly allocated mutual agreement party style margin margin bottom text indent font size font family time roman frequency meeting will meet least once each calendar quarter during research term long conducting post research term development support activity style margin margin bottom text indent font size font family time roman decision making each party will have collective vote except otherwise provided this agreement will make decision consensus including determination that vivo target validation been that compound satisfies lead compound criterion that lead compound satisfies development compound criterion event fails reach unanimous agreement with respect particular matter within decision making authority then either party have such matter referred biogen idec head research head research will meet promptly negotiate good faith resolve such matter operational deadlock biogen idec head research head research unable resolve such operational deadlock within thirty nbsp such longer period time they agree biogen idec will have final decision making authority except that event operational deadlock involving achievement vivo target validation lead compound criterion development compound criterion which belief such criterion have been biogen idec matter style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman will referred authorized executive officer party resolution such authorized executive officer unable resolve such operational deadlock within thirty nbsp such longer period they agree matter will then referred independent third party expert independent expert final determination biogen idec shall select independent expert within twenty nbsp after expiration such thirty nbsp period extended mutual agreement applicable resolve operational deadlock shall render determination within nbsp after selection party biogen idec unable agree independent expert then biogen idec notice each other shall each select independent expert resolve operational deadlock such independent expert shall render their determination within nbsp selection first independent expert either biogen idec fail appoint such independent expert within twenty nbsp after other party delivered notice selection independent expert then independent expert appointed party that first delivered notice shall make determination such determination shall govern independent expert appointed they agree upon resolution operational deadlock then their joint determination shall govern independent expert appointed unable agree upon resolution operational deadlock within nbsp period rendering their determination then independent expert shall within five nbsp thereafter select third independent expert third independent expert shall make determination within nbsp following such independent expert appointment decision independent expert shall rendered writing shall signed such independent expert final decision shall conclusive final deemed determination cost engaging independent expert will shared equally party style margin margin bottom text indent font size font family time roman other meeting addition meeting party will provide each other with regular update result research program through project team meeting meeting similar working group designated held than once month unless otherwise mutually agreed during research term will also facilitate active participation research program daniel finley randall king such other scientific founder biogen idec reasonably request including participation finley king meeting project team such other meeting party elect review research program style margin margin bottom text indent font size font family time roman compound designation style margin margin bottom text indent font size font family time roman lead compound during research term will regularly progress compound towards achieving lead compound criterion upon determination that compound satisfies lead compound criterion biogen idec will have right designate such compound lead compound time during research term style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman development compound during research term will regularly progress lead compound towards achieving development compound criterion upon determination that lead compound satisfies development compound criterion biogen idec will have right designate such lead compound development compound time during research term notwithstanding foregoing biogen idec will continue have right designate development compound time during term lead compound that nbsp biogen idec proprietary compound nbsp biogen idec designated back compound during research term described section nbsp during research term biogen idec will maintain written inventory compound that biogen idec proprietary compound that used research program which will provide each meeting research term biogen idec will provide final inventory biogen idec proprietary compound that were used research program style margin margin bottom text indent font size font family time roman back compound biogen idec discretion time during research term designate nbsp number development compound nbsp number lead compound that biogen idec proprietary compound nbsp lead compound that biogen idec proprietary compound back compound with respect development compound such development compound primary development compound biogen idec determines sole discretion based criterion similar biogen idec make determination with respect therapeutic program taking into account such factor development feasibility commercial viability intellectual property protection that development primary development compound yielded sufficient progress that development activity with respect such primary development compound should discontinued then biogen idec designate back compound such primary development compound substitute such primary development compound such back compound will then considered primary development compound such case discontinued primary development compound will deemed back compound such primary development compound order maintain lead compound back compound biogen idec will required establish that using commercially reasonable effort applicable back compound connection with development such back compound style margin margin bottom text indent font size font family time roman discontinued collaboration compound nbsp compound designated biogen idec discontinued collaboration compound time research term nbsp compound other than biogen idec proprietary compound designated biogen idec lead compound research term nbsp lead compound other than lead compound that biogen idec proprietary compound designated biogen idec development compound back compound research term will each style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman case automatically become discontinued collaboration compound each discontinued collaboration compound nbsp would longer lead compound purpose this agreement nbsp would excluded from scope license grant under section addition biogen idec would have right designate discontinued collaboration compound lead compound development compound avoidance doubt biogen idec proprietary compound never considered discontinued collaboration compound during research term will maintain written inventory discontinued collaboration compound which will provide upon request biogen idec research term will provide final inventory discontinued collaboration compound style margin margin bottom text indent font size font family time roman limitation avoidance doubt biogen idec will have right designate compound lead compound after expiration research term addition biogen idec will have right designate lead compound development compound after expiration research term except nbsp lead compound that were designated back compound during research term described section nbsp nbsp biogen idec proprietary compound style margin margin bottom font size font family time roman align center development style margin margin bottom text indent font size font family time roman sole development compound style margin margin bottom text indent font size font family time roman disclosure assistance sole development compound promptly following designation development compound which exercise development option under section nbsp which exercised development option under section nbsp then exercise phase development termination option under section nbsp each sole development compound will provide reasonable assistance biogen idec with respect practice licensed technology related each such sole development compound extent already done without limiting foregoing will nbsp disclose biogen idec within date which biogen idec designates sole development compound item licensed technology related such sole development compound that exist tangible form writing including electronic medium were previously disclosed biogen idec hereunder nbsp make personnel reasonably available provide answer biogen idec question during normal business hour assist biogen idec understanding implementing such licensed technology order biogen idec commence continue development such sole development compound contemplated this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman diligence biogen idec agrees commercially reasonable effort will cause sublicensees commercially reasonable effort initiate pursue development seek regulatory approval least nbsp licensed product each sole development compound designated under section nbsp other than development compound designated biogen idec back compound section nbsp least nbsp indication major market country style margin margin bottom text indent font size font family time roman responsibility development sole development compound sole licensed product biogen idec will commercially reasonable effort initiate continue development sole development compound promptly upon designation will inform time initiate development indication which such licensed product being developed each which will deemed confidential information biogen idec biogen idec will have sole right responsibility will have full control authority over sole cost expense development sole development compound licensed product containing consisting each such sole development compound each sole licensed product including making strategic tactical decision with respect thereto conducting development activity establishing method mean which performs such activity under this agreement biogen idec sole discretion delegate work performed development such sole licensed product collaborator other third party consultant clinical investigator service provider each case agreement having term inconsistent with term this agreement including term relating confidentiality intellectual property right provided that biogen idec shall remain responsible hereunder performance such person style margin margin bottom text indent font size font family time roman additional milestone style margin margin bottom margin left text indent font size font family time roman addition foregoing biogen idec will commercially reasonable effort achieve each development milestone from harvard license that listed exhibit harvard development milestone with regard each sole licensed product provided that biogen idec will default obligation under this section nbsp reason that biogen idec sublicensee failed achieve such milestone factor beyond control including without limitation nbsp force majeure nbsp delay attributable biogen idec sublicensee their affiliate change regulatory requirement regulatory process including without limitation such delay change associated with obtaining approval development commercialization from regulatory authority nbsp unavailability supply material product nbsp adverse clinical clinical result with respect licensed product term safety efficacy nbsp change legal requirement nbsp inability identify develop style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom margin left font size font family time roman suitable formulation licensed product nbsp unanticipated problem with manufacturing process scale licensed product provided further that event that biogen idec materially breached diligence obligation under this section nbsp with respect licensed product shall only have right terminate this agreement with respect such licensed product with respect other licensed product which biogen idec breach diligence obligation under this section nbsp style margin margin bottom margin left text indent font size font family time roman subject section nbsp biogen idec itself through sublicensees fails meet harvard development milestone within applicable time period then biogen idec will cooperate with complying with procedure section harvard license including assisting presenting harvard explanation plan such term defined harvard license that acceptable harvard biogen idec agrees reimburse payment that make harvard under section nbsp harvard license that necessary thereunder avoid delay termination harvard license maximum extent permitted which reimbursement payment will refundable will creditable biogen idec against next milestone payment that become payable biogen idec under this agreement with respect sole licensed product style margin margin bottom text indent font size font family time roman development plan sole development compound sole licensed product summary report biogen idec will prepare maintain annual development plan covering each sole development compound sole licensed product sole development plan will provide with copy such sole development plan annually well subsequent material update change thereto additionally within after each calendar year biogen idec shall furnish with summary written report summarizing effort effort sublicensees during prior calendar year develop sole licensed product which report will include summary intended effort then current calendar year will contain sufficient detail whether biogen idec compliance with obligation section nbsp notwithstanding anything contrary foregoing undergoes change control with operating entity that directly engaged research development commercialization product service treatment disease central nervous system human other than solely pursuant this agreement result change control competitor biogen idec will have further obligation provide sole development plan will continue provide annual summary report successor style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman post research term development support activity sole developed compound biogen idec wish conduct research activity with respect sole development compound after research term such identification validation biomarkers other measure pharmacodynamic outcome post research term development support activity party will negotiate good faith agree upon appropriate compensation other commercially reasonable term with respect such activity style margin margin bottom text indent font size font family time roman development diligence development compound style margin margin bottom text indent font size font family time roman general biogen idec each agree commercially reasonable effort biogen idec case will cause sublicensees commercially reasonable effort initiate pursue development seek regulatory approval least nbsp licensed product each development compound designated under section nbsp other than development compound designated biogen idec back compound section nbsp least nbsp indication major market country biogen idec will work together produce within after each calendar year summary written report summarizing party effort effort biogen idec sublicensees during prior calendar year develop developed licensed product which report will include summary intended effort then current calendar year will contain sufficient detail each party whether other party compliance with obligation under this section nbsp style margin margin bottom text indent font size font family time roman additional milestone style margin margin bottom margin left text indent font size font family time roman addition foregoing biogen idec will each commercially reasonable effort achieve each applicable harvard development milestone within applicable time period provided that neither party will default obligation under this section nbsp reason that such party sublicensee failed achieve such milestone factor beyond control including without limitation nbsp force majeure nbsp delay attributable such party sublicensee their affiliate change regulatory requirement regulatory process including without limitation such delay change associated with obtaining approval development commercialization from regulatory authority nbsp unavailability supply material product nbsp adverse clinical clinical result with respect licensed product term safety efficacy nbsp change legal requirement nbsp inability identify develop suitable formulation licensed product nbsp unanticipated problem with manufacturing process scale licensed product style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom margin left text indent font size font family time roman party themselves through sublicensees fail meet harvard development milestone within such specified time period then party will cooperate with each other complying with procedure section harvard license including working together present harvard explanation plan such term defined harvard license that acceptable harvard such failure meet harvard milestone solely biogen idec action omission biogen idec agrees reimburse payment that make harvard under section nbsp harvard license that necessary thereunder avoid delay termination harvard license maximum extent permitted which reimbursement payment will refundable will treated biogen idec development cost with respect affected developed licensed product such failure meet harvard milestone solely action omission will bear such cost such cost will treated development cost with respect affected developed licensed product such failure meet harvard milestone action omission both party party will split such cost such cost will treated development cost each party style margin margin bottom text indent font size font family time roman development compound licensed product style margin margin bottom text indent font size font family time roman manufacture development compound licensed product biogen idec exclusive right manufacture development compound corresponding licensed product itself through more affiliate third party selected biogen idec sole discretion style margin margin bottom text indent font size font family time roman responsibility regulatory filing development compound licensed product biogen idec will have sole right responsibility preparing filing regulatory filing with respect development compound corresponding licensed product territory name interacting with regulatory authority with respect such regulatory filing reporting regulatory authority adverse event related development compound corresponding licensed product extent required applicable regulation each case except only extent such activity assigned under duly approved development plan accordance with section nbsp regulatory approval licensed product will solely owned biogen idec style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center commercialization style margin margin bottom text indent font size font family time roman sole licensed product style margin margin bottom text indent font size font family time roman responsibility commercialization sole licensed product biogen idec will inform least prior expected regulatory approval each sole licensed product with respect each indication which such sole licensed product receives regulatory approval which will deemed confidential information biogen idec biogen idec will have sole right responsibility will have full control authority over sole cost expense commercialization each sole licensed product including making strategic tactical decision with respect thereto conducting commercialization activity establishing method mean which performs such activity under this agreement biogen idec sole discretion delegate work performed commercialization such sole licensed product collaborator other third party consultant service provider each case agreement having term inconsistent with term this agreement including term relating confidentiality intellectual property right provided that biogen idec shall remain responsible hereunder performance such person style margin margin bottom text indent font size font family time roman diligence biogen idec will commercially reasonable effort will cause sublicensees commercially reasonable effort initiate pursue commercialization each sole licensed product every major market country where receives regulatory approval style margin margin bottom text indent font size font family time roman commercialization plan sole licensed product biogen idec will prepare maintain commercialization plan covering each sole development compound sole licensed product sole commercialization plan will provide with copy such sole commercialization plan annually well subsequent material update change thereto additionally within after each calendar year biogen idec shall furnish with summary written report summarizing effort effort sublicensees during prior calendar year commercialize sole licensed product which report will include summary intended effort then current calendar year will contain sufficient detail whether biogen idec compliance with obligation under section nbsp notwithstanding anything contrary foregoing undergoes change control with competitor biogen idec will have further obligation provide sole commercialization plan will continue provide annual summary report successor style margin margin bottom text indent font size font family time roman commercialization diligence commercialized product biogen idec will commercially reasonable effort biogen idec will cause sublicensees commercially reasonable effort initiate pursue commercialization each commercialized product every major market country where receives regulatory approval biogen idec will work together produce within after each style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman calendar year written report summarizing party effort effort biogen idec sublicensees during prior calendar year commercialize commercialized product which report will include summary intended effort then current calendar year will contain sufficient detail each party whether other party compliance with obligation under this section nbsp style margin margin bottom text indent font size font family time roman trademark promotional material style margin margin bottom text indent font size font family time roman general subject section nbsp biogen idec will have right sole discretion select trademark service mark used conjunction with licensed product sold biogen idec design produce promotional material licensed product sold behalf biogen idec including limited package insert data sheet leaflet advertisement labeling will have right upon written request informed such trademark service mark receive sample such promotional material used major market country each which will until first used commerce deemed confidential information biogen idec will reason including commerce trademark service mark selected biogen idec disclosed under this section nbsp style margin margin bottom text indent font size font family time roman commercialized product requested subject applicable biogen idec will include name designated trademark promotional material commercialized product sold behalf biogen idec united state including package insert data sheet leaflet advertisement labeling biogen idec will name designated trademark other reason including commerce style margin margin bottom font size font family time roman align center development commercialization option style margin margin bottom text indent font size font family time roman development option option develop each development compound with biogen idec development option biogen idec will prepare present overview anticipated preclinical toxicology early clinical development study consistent with biogen idec standard program similar stage each development compound within after such compound been designated development compound exercise development option with respect particular development compound must notify biogen idec writing later than following such compound designation development compound later following receipt overview such development compound upon exercise development option development compound party will thereafter share proportionally cost develop obtain regulatory approval such development compound worldwide basis through profit share mechanism described section nbsp developed licensed product style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman formation development plan medical affair plan style margin margin bottom text indent font size font family time roman upon exercise development option development compound each development compound party will form joint development committee comprised equal number representative from senior clinical research management each party review oversee development such development compound including nbsp establishing directing strategy worldwide development such development compound nbsp creating reviewing finalizing development plan such development compound proposing revision such development plan needed frequently than annually nbsp subject within parameter development plan nbsp overseeing implementation development plan including approval clinical trial protocol review conduct clinical trial conducted pursuant development plan nbsp reviewing approving overall strategy positioning material submission filing with applicable regulatory authority nbsp performing such other duty party designate style margin margin bottom text indent font size font family time roman will make decision consensus event fails reach unanimous agreement with respect particular matter within decision making authority then either party have such matter referred head development each party will meet promptly negotiate good faith resolve such matter head development unable resolve such matter within thirty nbsp such longer period time they agree matter will referred authorized executive officer party resolution disagreement resolved such officer biogen idec will have final decision making authority style margin margin bottom text indent font size font family time roman biogen idec will prepare consultation with review described above written plan budget development each development compound development plan avoidance doubt biogen idec will have final decision making right regarding content development execution development plan style margin margin bottom text indent font size font family time roman party will also jointly develop execute plan medical affair activity supporting each development compound both post approval each medical affair plan cost such activity will shared proportionally party through profit share mechanism described section nbsp developed licensed product avoidance doubt biogen idec will have final decision making right regarding content development execution medical affair plan style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman development option termination will have right terminate right obligation with regard development development compound providing written notice biogen idec within after issuance final clinical trial report first phase trial such development compound phase development termination option upon providing such notice affected development compound will deemed sole development compound will have further obligation hereunder share cost development such sole development compound that accrue after effective date such notice avoidance doubt nothing this section nbsp will limit share liability under section nbsp exhibit cost that accrued prior effective date such notice style margin margin bottom text indent font size font family time roman commercialization option each licensed product containing consisting development compound which successfully complied with development obligation developed licensed product exercised phase development termination option provided section nbsp will also have option commercialize such developed licensed product united state with biogen idec commercialization option which will include activity undertaken before after regulatory approval that relate marketing promoting distributing offering sale selling developed licensed product biogen idec will prepare present draft commercialization plan each developed licensed product within after date receipt final report first phase trial such developed licensed product that designed support regulatory approval united state exercise commercialization option with respect particular developed licensed product will notify biogen idec writing earlier than date receipt such final report later than after such date later following receipt draft commercialization plan such developed licensed product each such developed licensed product which exercise commercialization option shall referred commercialized product notifies biogen idec within such period party will negotiate good faith enter into soon reasonably possible separate commercialization agreement covering party respective right obligation such commercialization that includes term forth exhibit with regard developed licensed product either nbsp fails provide notice biogen idec intention exercise commercialization option within aforementioned period nbsp prior expiration such period provides notice biogen idec that intend exercise commercialization option then will have further right commercialize such developed licensed product style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman formation commercialization plan style margin margin bottom text indent font size font family time roman upon exercise commercialization option developed licensed product party will form joint commercialization committee comprised equal number representative from senior commercial management each party review oversee commercialization such commercialized product including nbsp reviewing approving commercialization plan each commercialized product each commercialization plan which will consistent with commercialization agreement described section nbsp exhibit nbsp subject within parameter commercialization plan overseeing implementation commercialization plan nbsp performing such other duty party designate style margin margin bottom text indent font size font family time roman will make decision consensus event fails reach unanimous agreement with respect particular matter within decision making authority then either party have such matter referred head commercialization each party will meet promptly negotiate good faith resolve such matter head commercialization unable resolve such matter within thirty nbsp such longer period time they agree matter will referred authorized executive officer party resolution disagreement resolved such officer biogen idec will have final decision making authority style margin margin bottom text indent font size font family time roman upon exercise commercialization option developed licensed product biogen idec will prepare consultation with commercialization plan each commercialized product which will reviewed approved each such plan will reasonable detail nbsp overall strategy with respect marketing promoting distributing obtaining reimbursement applicable commercialized product united state nbsp activity conducted responsibility each party connection with commercialization applicable commercialized product nbsp fair reasonable allocation between party such activity forth exhibit including direct participation customer facing activity avoidance doubt subject exhibit biogen idec will have final decision making right regarding content development execution commercialization plan style margin margin bottom text indent font size font family time roman commercialization option termination withdraw from continued participation commercialization activity united state with respect more commercialized product providing biogen idec with prior written notice unless shorter time period mutually agreed party party right obligation result such withdrawal shall forth commercialization agreement described section nbsp exhibit style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center payment style margin margin bottom text indent font size font family time roman upfront annual maintenance style margin margin bottom text indent font size font family time roman upfront biogen idec will refundable creditable front aggregate amount million five hundred thousand dollar upfront payable wire transfer immediately available fund within thirty nbsp after effective date accordance with wire transfer instruction provided writing biogen idec section nbsp style margin margin bottom text indent font size font family time roman annual maintenance biogen idec will payable wire transfer immediately available fund january nbsp each calendar year provided that during research term period when biogen idec developing development compound licensed product such shall cost that shared party accordance with section applicable will refund such amount when particular calendar year able recoup full amount payment harvard under section nbsp harvard license accordance with term thereof style margin margin bottom text indent font size font family time roman equity investment biogen idec will within thirty nbsp after effective date enter into agreement agreement under which biogen idec will make equity investment which investment will made same security valuation most recent previous round financing forth second series convertible preferred stock purchase agreement dated nbsp part such investment biogen idec will receive same right obligation with respect purchased security will party same stockholder agreement other equity document other equity investor such previous round financing style margin margin bottom text indent font size font family time roman research funding payment style margin margin bottom text indent font size font family time roman budget will provide funding nbsp number ftes forth research plan perform activity contemplated each year research term rate purpose determining cost incurred with respect personnel performing work under research program nbsp number biogen idec ftes forth research plan perform activity contemplated each year research term rate purpose determining cost incurred biogen idec with respect biogen idec personnel performing work under research program nbsp reimbursement external cost incurred biogen idec accordance with research plan biogen idec will responsible fifty percent nbsp cost budget will responsible forty nine percent nbsp cost budget style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman within after each calendar quarter party will deliver written report each other setting forth actual number ftes dedicated external cost incurred research program such calendar quarter total quarterly expense event that total quarterly expense party invoicing party were excess applicable share budget biogen idec invoicing party will submit other party invoice difference between their respective total quarterly expense applicable share budget which will paid within receipt reconciliation payment provided however that invoicing party total quarterly expense exceeded more than amount allocated under budget such calendar quarter such excess otherwise agreed other party then other party will have right disregard such excess purpose reconciliation payment style margin margin bottom text indent font size font family time roman party acknowledge agree that nbsp that submitted sbir grant application entitled sbir grant nbsp agreed that awarded sbir grant will accept funding awarded under such sbir grant such funding foregone grant amount nbsp biogen idec agrees that include forgone grant amount invoice forgone grant calendar quarter part total quarterly expense addition total quarterly expense that would otherwise calculated forth section nbsp such calendar quarter that full amount such forgone grant amount shall deemed excess applicable share budget such calendar quarter excess amount allocated under budget such calendar quarter shall shared party accordance with section nbsp used herein forgone grant calendar quarter mean calendar quarter which sbir grant awarded such foregone calendar quarter occurs during calendar year first calendar quarter further party agree that forgone grant amount shall exceed style margin margin bottom text indent font size font family time roman during first nbsp year research program anticipated that research plan will require ftes biogen idec ftes notwithstanding above paragraph during first nbsp year research program style margin margin bottom text indent font size font family time roman actual number ftes than ftes then nbsp reconciliation payment will made ftes were billable nbsp difference payment between what biogen idec paid what biogen idec should have paid based actual will deducted from biogen idec future development milestone payment sale milestone payment royalty payment provided that individual biogen idec style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman milestone royalty payment reduced more than with remaining obligation reflected against future biogen idec milestone royalty payment until remaining obligation owes biogen idec been paid full style margin margin bottom text indent font size font family time roman actual number biogen idec ftes more than ftes then nbsp reconciliation payment will made biogen idec ftes were billable nbsp difference payment between what paid biogen idec what should have paid biogen idec based actual will deducted from biogen idec future development milestone payment sale milestone payment royalty payment provided that individual biogen idec milestone royalty payment reduced more than with remaining obligation reflected against future biogen idec milestone royalty payment until remaining obligation owes biogen idec been paid full style margin margin bottom text indent font size font family time roman notwithstanding above during year research program actual number biogen idec ftes exceeds actual number ftes then biogen idec will charge difference ftes difference payment between what paid biogen idec what should have paid biogen idec based actual will deducted from biogen idec future development milestone payment sale milestone payment royalty payment provided that individual biogen idec milestone royalty payment reduced more than with remaining obligation reflected against future biogen idec milestone royalty payment until remaining obligation owes biogen idec been paid full style margin margin bottom text indent font size font family time roman purpose section each year research program will deemed begin effective date anniversary style margin margin bottom text indent font size font family time roman milestone payment style margin margin bottom text indent font size font family time roman vivo target validation within forty five nbsp following achievement vivo target validation biogen idec will make time payment style margin margin bottom text indent font size font family time roman development compound milestone style margin margin bottom text indent font size font family time roman biogen idec will make payment within following each designation biogen idec lead compound development compound each development compound milestone payment purpose clarity development compound milestone payment will paid back compound that replaces primary development compound which development compound milestone payment already been paid style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman second year research program submitted lead compound that meet development compound criterion submitted such lead compound within such time subsequently determines that such lead compound meet development compound criterion through decision making escalation process forth section nbsp therefore designated biogen idec development compound then with respect licensed product that contains first lead compound designated development compound licensed product that contains back compound such first development compound above development compound milestone payment will reduced calendar quarter each calendar quarter that determination that first lead compound development compound criterion delayed after such second year research plan clarity nbsp above reduction will calculated multiplying applicable development compound milestone payment above same number time there were calendar quarter delay nbsp submission made appropriately address development compound criterion determines that lead compound meet development compound criterion calendar quarter that later than calendar quarter which made such submission date submission such complete information such lead compound will date determination purpose calculating reduction development compound milestone payment under this section nbsp style margin margin bottom text indent font size font family time roman development milestone style margin margin bottom text indent font size font family time roman payment biogen idec will make following payment each development milestone payment within following first occurrence applicable event listed below each licensed product achieve such event each nbsp nbsp development milestone event purpose clarity development milestone payment will only paid font style white space nowrap back font compound discontinued primary development compound replaced such back compound previously achieve such milestone style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman milestone valign bottom nbsp nbsp valign bottom align center style border bottom solid payment style font family time roman font size valign dosing first subject first phase trial such licensed product valign bottom nbsp nbsp valign align center style font size height height colspan style font family time roman font size valign dosing first subject first phase trial such licensed product valign bottom nbsp nbsp valign align center style font size height height colspan style font family time roman font size valign dosing first subject first phase trial such licensed product valign bottom nbsp nbsp valign align center style font size height height colspan style font family time roman font size valign regulatory approval such licensed product valign bottom nbsp nbsp valign align center style font size height height colspan style font family time roman font size valign regulatory approval such licensed product first major market country valign bottom nbsp nbsp valign align center style font size height height colspan style font family time roman font size valign regulatory approval such licensed product valign bottom nbsp nbsp valign align center table style margin margin bottom text indent font size font family time roman second year research program submitted lead compound that meet development compound criterion submitted such lead compound within such time subsequently determines that such lead compound meet development compound criterion through decision making escalation process forth section nbsp therefore designated biogen idec development compound then with respect licensed product that contains consists first lead compound designated development compound licensed product that contains consists back compound such first development compound above development milestone payment will reduced calendar quarter each calendar quarter that determination that first lead compound development compound criterion delayed after such second year research plan clarity nbsp above reduction will calculated multiplying applicable development milestone payment above same number time there were calendar quarter delay nbsp submission made appropriately address development compound criterion determines that lead compound meet development compound criterion calendar quarter that later than calendar quarter which made such submission date submission such complete information such lead compound will date determination purpose calculating reduction development milestone payment under this section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman sale milestone style margin margin bottom text indent font size font family time roman biogen idec will following payment within after applicable calendar year when annual sale each sole licensed product given calendar year first reach respective threshold indicated below style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman milestone valign bottom nbsp nbsp valign bottom align center style border bottom solid payment style font family time roman font size valign annual sale given calendar year exceeding valign bottom nbsp nbsp valign bottom align center style font size height height colspan style font family time roman font size valign annual sale given calendar year exceeding valign bottom nbsp nbsp valign bottom align center table style margin margin bottom text indent font size font family time roman clarity nbsp annual sale sole licensed product exceed given calendar year exceeded prior calendar year then biogen idec will make time payment under this section nbsp with respect such sole licensed product nbsp sale milestone will payable respect sale developed licensed product commercialized product style margin margin bottom text indent font size font family time roman second year research program submitted lead compound that meet development compound criterion submitted such lead compound within such time subsequently determines that such lead compound meet development compound criterion through decision making escalation process forth section nbsp therefore designated biogen idec development compound then with respect licensed product that contains consists first lead compound designated development compound licensed product that contains consists back compound such first development compound above sale milestone payment will reduced calendar quarter each calendar quarter that determination that first lead compound development compound criterion delayed after such second year research plan clarity nbsp above reduction will calculated multiplying applicable sale milestone payment above same number time there were calendar quarter delay nbsp submission made appropriately address development compound criterion determines that lead compound meet development compound criterion calendar quarter that later than calendar quarter which made such submission date submission such complete information such lead compound will date determination purpose calculating reduction sale milestone payment under this section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman notice payment milestone biogen idec will provide with prompt written notice upon occurrence each milestone event forth this section nbsp style margin margin bottom text indent font size font family time roman royalty payment sole licensed product style margin margin bottom text indent font size font family time roman during applicable royalty term subject section nbsp sole licensed product sole licensed product basis biogen idec will royalty based annual sale each sole licensed product following rate style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman annual sale valign bottom nbsp nbsp valign bottom align center style border bottom solid payment style font family time roman font size valign annual sale including valign bottom nbsp nbsp valign bottom align center style font size height height colspan style font family time roman font size valign annual sale above including valign bottom nbsp nbsp valign bottom align center style font size height height colspan style font family time roman font size valign annual sale above including valign bottom nbsp nbsp valign bottom align center style font size height height colspan style font family time roman font size valign annual sale above valign bottom nbsp nbsp valign bottom align center table style margin margin bottom text indent font size font family time roman second year research program submitted lead compound that meet development compound criterion submitted such lead compound within such time subsequently determines that such lead compound meet development compound criterion through decision making escalation process forth section nbsp therefore designated biogen idec development compound then with respect licensed product that contains consists first lead compound designated development compound licensed product that contains consists back compound such first development compound above royalty payment will reduced calendar quarter each calendar quarter that determination that first lead compound development compound criterion delayed after such second year research plan clarity nbsp above reduction will calculated multiplying applicable royalty above same number time there were calendar quarter delay nbsp submission made appropriately address development compound criterion determines that lead compound meet development compound criterion calendar quarter that later than calendar quarter which made such submission date submission such complete information such lead compound will date determination purpose calculating reduction royalty payment under this section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman clarity royalty will payable respect sale developed licensed product profit share provision section nbsp will apply instead style margin margin bottom text indent font size font family time roman adjustment royalty style margin margin bottom text indent font size font family time roman exercise phase development termination option then royalty sole licensed product listed above will increased point each royalty tier which point increase will subject anti stacking adjustment third party obligation described section nbsp style margin margin bottom text indent font size font family time roman biogen idec affiliate biogen idec obtains license from third party infringed reasonably necessary after length negotiation regardless whether biogen idec obtains such license prior after date issuance applicable patent application then biogen idec offset royalty payment thereunder with respect sale sole licensed product particular country against royalty payment that with respect sale such sole licensed product such country sublicensee biogen idec obtains license from third party that biogen idec other affiliate sublicensee biogen idec infringed reasonably necessary after length negotiation regardless whether obtained prior after issuance applicable patent application biogen idec allows such sublicensee offset percentage amount otherwise payable biogen idec such affiliate sublicensee with respect sale sole licensed product particular country then biogen idec offset same percentage against royalty payment that with respect sale such sole licensed product such country disagreement whether such intellectual property constitutes infringed reasonably necessary will referred final determination independent patent attorney with requisite experience expertise selected patent coordinator using process described section nbsp above notwithstanding event shall nbsp royalty payment with respect such sole licensed product reduced more than amount otherwise nbsp percentage offset that biogen idec entitled make against royalty payment greater than percentage offset that biogen idec entitled make against royalty payment such third party licensor account royalty payment made with respect such sole licensed product with respect sale sole licensed product biogen idec biogen idec affiliate their respective sublicensees applies third party royalty adjustment described this section nbsp result fact that component such sole licensed product covered infringed reasonably necessary then biogen idec such biogen idec affiliate such biogen idec sublicensee also classify such sole licensed product combination product described section nbsp solely result addition such component example only finished product contains active ingredient both nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman compound that sole licensed product nbsp delivery technology that covered infringed reasonably necessary owned third party licensor biogen idec such biogen idec affiliate such biogen idec sublicensee offset royalty owed such third party with respect such delivery technology accordance with this section nbsp also classify such sole licensed product combination product solely result addition such delivery technology another example only situation described immediately preceding sentence sole licensed product also includes second active ingredient that covered infringed reasonably necessary owned third party licensor then biogen idec such biogen idec affiliate such biogen idec sublicensee nbsp offset royalty owed such third party with respect delivery technology described immediately preceding sentence accordance with this section nbsp nbsp treat resulting product combination product where second active ingredient other part combination product purpose calculation under section nbsp nbsp take additional deduction royalty paid delivery technology style margin margin bottom text indent font size font family time roman extent that royalty sole licensed product that either covered valid claim entitled data protection particular country where generic product enters market then such royalty such country will reduced follows style margin margin bottom text indent font size font family time roman following first commercial sale generic product applicable country sale applicable licensed product such country reduced amount equal greater than than sale such licensed product last full calendar quarter prior such first commercial sale such generic product style margin margin bottom text indent font size font family time roman following first commercial sale generic product applicable country sale applicable licensed product such country reduced amount equal greater than sale such licensed product last full calendar quarter prior such first commercial sale such generic product style margin margin bottom text indent font size font family time roman event will royalty adjustment generic product competition third party obligation reduce royalty payable above more than aggregate style margin margin bottom text indent font size font family time roman patent challenge biogen idec sublicensee their affiliate commences action which challenge validity enforceability scope licensed patent challenge proceeding royalty rate specified section nbsp will style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman increased point with respect sale licensed product that covered licensed patent that subject challenge proceeding that sold during pendency such challenge proceeding outcome such challenge proceeding determination favor nbsp royalty rate specified section nbsp with respect sale licensed product that covered licensed patent that subject such challenge proceeding shall remain such increased rate nbsp biogen idec shall reimburse shall cause such affiliate sublicensee applicable reimburse expense incurred including reasonable attorney connection with such challenge proceeding outcome such challenge proceeding determination favor biogen idec such affiliate sublicensee applicable biogen idec such affiliate sublicensee applicable shall have right recoup increased royalty paid pursuant this section nbsp during pendency such challenge proceeding style margin margin bottom text indent font size font family time roman profit share developed licensed product style margin margin bottom text indent font size font family time roman notwithstanding anything contrary this agreement biogen idec will share operating profit operating loss arising from each developed licensed product basis biogen idec which will calculated provided exhibit style margin margin bottom text indent font size font family time roman event that exercise development option with respect licensed product exercise phase development termination option party launch such licensed product territory will repay development milestone previously paid biogen idec with respect such licensed product equal amount over course first year commercialization such amount will against quarterly payment under exhibit provided that such quarterly payment sufficient cover repayment amount applicable quarter will biogen idec difference between payment under exhibit repayment amount applicable quarter style margin margin bottom text indent font size font family time roman withholding rule regulation require withholding imposed upon payment forth this section nbsp biogen idec will make such withholding payment required subtract such withholding payment from amount otherwise paid biogen idec will withhold only such amount required withheld applicable country from which payment being made biogen idec will promptly notify such withholding will furnish with copy certificate other documentation evidencing such withholding promptly upon receipt such documentation biogen idec biogen idec will commercially reasonable effort minimize such withholding will reasonably cooperate with completing filing document style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman required under provision applicable under other applicable connection with claim refund credit such withholding avoidance doubt used this section nbsp biogen idec will include affiliate biogen idec whom payment obligation under this section nbsp assigned accordance with term this agreement style margin margin bottom text indent font size font family time roman currency payment amount paid biogen idec pursuant this agreement will made united state dollar through wire transfer bank account designated amount royalty earned will first determined currency country which such royalty earned then converted equivalent such amount united state dollar conversion foreign currency united state dollar will made applying monthly average rate exchange calculated using foreign exchange rate published bloomberg during applicable month starting nbsp business before beginning such month ending nbsp business before such month utilized biogen idec accordance with generally accepted accounting principle fairly applied employed consistent basis throughout biogen idec operation such payment will without deduction exchange collection other charge style margin margin bottom text indent font size font family time roman time payment late unless otherwise specified this agreement payment from biogen idec will considered within event occurrence triggering such biogen idec payment obligation payment biogen idec that paid before date such payment under this agreement will bear interest rate annum equal lesser nbsp rate announced bank america successor prime rate effect date that such payment would have been first nbsp maximum rate permissible under applicable interest will accrue beginning first following date payment will compounded quarterly payment such interest biogen idec shall limit right exercise other remedy have consequence lateness payment style margin margin bottom text indent font size font family time roman currency restriction restriction transfer currency exist country which licensed product sold that prevent biogen idec from making royalty payment thereon united state dollar biogen idec will promptly notify condition preventing such transfer will make royalty payment sale such country local currency deposit local bank other depository designated writing absence such designation recognized banking institution selected biogen idec identified biogen idec written notice style margin margin bottom text indent font size font family time roman report royalty payment licensed product will deemed sold purpose this agreement when invoiced biogen idec affiliate sublicensees third style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman party royalty payment from biogen idec will paid within following each partial full calendar quarter during which sale licensed product were made each royalty payment will accompanied written report setting forth nbsp number unit each licensed product sold leased otherwise transferred biogen idec sublicensees their respective affiliate applicable calendar quarter nbsp gross amount licensed product sold leased otherwise transferred biogen idec sublicensees their respective affiliate during applicable calendar quarter nbsp sale country country licensed product licensed product basis including itemized listing allowable deduction converted into united state dollar accordance with section nbsp nbsp gross combination product sold leased otherwise transferred biogen idec sublicensees their respective affiliate during applicable calendar quarter together with basis calculation sale such combination product nbsp amount adjustment such royalty accordance with section nbsp nbsp amount withheld accordance with section nbsp resulting royalty payment total relevant calendar quarter royalty payment particular calendar quarter after first commercial sale licensed product biogen idec shall provide report that effect explaining basis payment being written report royalty payment made under this agreement will certified behalf biogen idec true correct complete material respect will confidential information biogen idec style margin margin bottom text indent font size font family time roman record commencing upon party obligation make royalty other payment pursuant this agreement submit total quarterly expense operating expense pursuant this agreement each party audited party will keep cause affiliate sublicensees keep accurate record sufficient detail enable other party auditing party verify amount royalty other payment made under this agreement audited party accuracy total quarterly expense operating expense charged audited party audited party affiliate sublicensees shall retain such record relating given calendar quarter least three nbsp year after conclusion that calendar quarter auditing party shall have right more than once during calendar year have audited party book record audited certified public accounting firm whom audited party give consent such audit which consent will withheld unreasonably also allow harvard participate such audit audit under this section nbsp will conducted during normal business hour upon least prior written notice sole purpose verifying amount royalty other payment paid audited party under this agreement amount total quarterly expense operating expense submitted audited party audited party will cause accounting firm enter into confidentiality agreement with auditing party harvard both case limit audit report auditing party harvard solely that information which will properly contained royalty report pursuant section nbsp style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman written report total quarterly expense pursuant section nbsp income statement reconciliation statement pursuant section nbsp exhibit auditing party will cost such audit provided however that event that audit pursuant this section nbsp show that audited party collectively underpaid auditing party amount which exceeds royalty other payment properly collectively auditing party under term this agreement then expense such independent accountant will borne audited party auditing party will promptly notify audited party such underpayment amount required correct such payment audited party will make applicable payment within overdue payment provision section nbsp will apply with respect such amount agrees exercise right inspect biogen idec record under this section nbsp same time harvard exercise right inspect such record under section nbsp harvard license provided that exercise such inspection right independently from harvard reasonably belief that biogen idec material breach payment obligation under this agreement style margin margin bottom text indent font size font family time roman wire transfer unless otherwise specified writing accordance with section nbsp payment required according this agreement will made wire transfer using following instruction style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign bank valign bottom valign bottom silicon valley bank style font family time roman font size valign valign bottom valign bottom tasman drive style font family time roman font size valign valign bottom valign bottom santa clara style font family time roman font size valign routing nbsp nbsp transit nbsp valign bottom valign bottom style font family time roman font size valign swift code valign bottom valign bottom international wire style font family time roman font size valign account valign bottom valign bottom style font family time roman font size valign beneficiary valign bottom valign bottom proteostasis therapeutic style font family time roman font size valign valign bottom valign bottom technology square suite style font family time roman font size valign valign bottom valign bottom cambridge table style margin margin bottom text indent font size font family time roman adjustment notwithstanding anything contrary this agreement addition other adjustment provided this section nbsp amount payable biogen idec under this section nbsp further modified provided section nbsp style margin margin bottom text indent font size font family time roman consolidation style margin margin bottom text indent font size font family time roman biogen idec determines pursuant generally accepted accounting principle applied united state that required consolidate result activity contemplated this agreement then biogen idec request nbsp will create wholly owned subsidiary subsidiary transfer licensed technology licensed biogen idec subsidiary nbsp this agreement will assigned subsidiary style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman following assignment this agreement subsidiary nbsp subsidiary will take action activity required this agreement nbsp will guarantee remain liable obligation subsidiary under this agreement nbsp payment made biogen idec will made subsidiary subsidiary will hold licensed technology such other asset liability related this agreement other asset perform obligation hereunder otherwise conduct activity incidental foregoing exclusion other activity behalf itself biogen idec affiliate third party will cause subsidiary covenant directly with biogen idec that will incur debt issue additional capital encumber licensed technology manner acquire additional asset other than ordinary course business performance this agreement permitted under this agreement long biogen idec required consolidate subsidiary account subsidiary will prepare deliver biogen idec accurate true financial record required biogen idec order meet financial reporting obligation will otherwise comply with section nbsp style margin margin bottom text indent font size font family time roman biogen idec determines that required consolidate subsidiary then following provision will apply style margin margin bottom text indent font size font family time roman will provide biogen idec financial information schedule subsidiary that required biogen idec external financial reporting disclosure accordance with biogen idec standard accounting procedure consistently applied internally prepared quarterly certification attesting completeness accuracy such information including evaluation effectiveness internal control biogen idec require meeting with financial representative least advance needing information this section nbsp agree document information provided reporting deadline methodology approach assumption estimate true process style margin margin bottom text indent font size font family time roman notwithstanding section nbsp later than business after each contract quarter during term will provide biogen idec income statement balance sheet cash flow statement unaudited actual result entire operation subsidiary other financial information schedule that required biogen idec external financial reporting disclosure accordance with biogen idec standard accounting procedure consistently applied which will consist estimate judgment that affect reported amount asset liability revenue expense related disclosure style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman reporting audit obligation under this section nbsp will remain place period which biogen idec determines pursuant generally accepted accounting principle applied united state that reasonably likely that will need consolidate subsidiary accordance with biogen idec standard accounting procedure consistently applied style margin margin bottom text indent font size font family time roman will ensure that subsidiary transfer within reasonable period time later than each calendar quarter cash excess amount required subsidiary perform under this agreement style margin margin bottom text indent font size font family time roman each calendar year during term subsidiary will biogen idec request have calendar year financial result audited reviewed nationally recognized accounting firm biogen idec will cost such audit review accepts biogen idec choice accounting firm otherwise cost such audit review will borne subsidiary will provide draft audited reviewed applicable financial statement including income statement balance sheet cash flow statement report independent auditor biogen idec within each such calendar year which biogen idec request audit review style margin margin bottom font size font family time roman align center ownership intellectual property license style margin margin bottom text indent font size font family time roman ownership intellectual property style margin margin bottom text indent font size font family time roman background intellectual property between party subject license granted under this agreement each party retains right title interest intellectual property right that such party owns control effective date that develops otherwise acquires after effective date outside scope this agreement without limiting generality foregoing subject license granted under this agreement nbsp biogen idec owns right title interest biogen idec background know biogen idec background patent right nbsp subject license granted biogen idec under this agreement ownership other right harvard under harvard license owns right title interest background know background patent right style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman collaboration technology style margin margin bottom text indent font size font family time roman biogen idec owns will right title interest biogen idec collaboration technology style margin margin bottom text indent font size font family time roman owns will right title interest collaboration technology style margin margin bottom text indent font size font family time roman party jointly will jointly joint collaboration technology subject license granted each party party other right obligation under this agreement each party will free exploit joint collaboration technology throughout world without restriction without need obtain further consent from other party without payment compensation other party style margin margin bottom text indent font size font family time roman invention assignment each party covenant agrees that employee affiliate employee acting under affiliate authority performance such party obligation hereunder shall obligated under binding written agreement established corporate policy assign such party such party shall direct intellectual property right discovered made conceived reduced practice such employee result such employee employment case others acting performance behalf such party with respect such party obligation hereunder such consultant subcontractor licensee sublicensees outside contractor clinical investigator agent employee working profit academic institution such others shall also obligated under agreement that meet criterion preceding sentence unless otherwise mutually approved party provided that case agreement with third party academic profit institution party will have fulfilled obligation under this sentence such agreement provides that contracting party obtains option obtain license intellectual property right discovered made conceived reduced practice third party course such agreement each party agrees undertake commercially reasonable effort enforce agreement referenced this section nbsp including where appropriate legal action considering among other thing commercial value such intellectual property right style margin margin bottom text indent font size font family time roman license grant style margin margin bottom text indent font size font family time roman research license biogen idec subject term condition this agreement grant biogen idec exclusive license with right grant sublicenses subject section nbsp under licensed technology solely conduct activity under research program with during research term research license style margin margin bottom text indent font size font family time roman development commercialization license biogen idec subject term condition this agreement effective upon designation biogen idec style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman development compound including limited back compound accordance with section grant biogen idec exclusive even royalty bearing license with right grant sublicenses subject section nbsp under licensed technology solely research develop make have made offer sell sell import export otherwise commercialize such development compound including limited back compound licensed product containing consisting such development compound back compound field territory development commercialization license provided however event that exercise development option with regard applicable development compound development commercialization license will exclusive with with regard applicable development compound back compound resulting licensed product clarity will grant third party license that will prevent from granting whole part development commercialization license biogen idec style margin margin bottom text indent font size font family time roman license subject term condition this agreement biogen idec grant exclusive royalty free license with right grant sublicenses subject section nbsp under biogen idec technology solely nbsp conduct activity under research program during research term nbsp event that exercise development option conduct development activity pursuant approved development plan nbsp event exercise commercialization option conduct commercial activity pursuant approved commercialization plan nbsp subject section nbsp research develop make have made offer sell sell import export otherwise commercialize discontinued development compound product containing discontinued development compound each case indication within excluded field avoidance doubt right obtained royalty free product under section will addition right granted under this section nbsp style margin margin bottom text indent font size font family time roman sublicense right style margin margin bottom text indent font size font family time roman biogen idec with respect compound that subject research program biogen idec sublicense right under section nbsp only collaborator qualified service provider until such compound designated development compound back compound with respect development compound back compound resulting licensed product biogen idec sublicense right under section nbsp third party provided that such sublicense must consistent with term this agreement biogen idec shall remain responsible performance those obligation under this agreement that sublicensed delegated affiliate sublicensees biogen idec shall ensure that such sublicense shall include harvard right audit book record such sublicensees relevant style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman payment obligation hereunder thereunder biogen idec shall deliver written notice such sublicenses together with copy executed sublicense agreement later than following granting such sublicense biogen idec redact from copy sublicenses provided hereunder term that applicable determination whether such sublicense consistent with term this agreement harvard license style margin margin bottom text indent font size font family time roman sublicense right under clause nbsp nbsp section nbsp only collaborator qualified service provider sublicense right under clause nbsp section nbsp third party with respect discontinued collaboration compound related product sublicense right granted under clause nbsp section nbsp third party provided that such sublicense must consistent with term this agreement shall remain responsible performance those obligation under this agreement that sublicensed delegated affiliate sublicensees shall deliver biogen idec written notice such sublicenses together with copy executed sublicense agreement later than following granting such sublicense redact from copy sublicenses provided biogen idec hereunder term that applicable determination whether such sublicense consistent with term this agreement harvard license obligation hereunder thereunder style margin margin bottom text indent font size font family time roman other right neither party grant right license under this agreement other party either expressly implication under intellectual property right information controlled that party except specifically forth this agreement style margin margin bottom text indent font size font family time roman third party license solely responsible keeping full force effect license with third party existing effective date that cover licensed technology including payment obligation owing third party under such license provided however that time where party sharing profit loss hereunder development licensed product commercialized product third party royalty payment obligation under such license will deemed shared cost under section nbsp exhibit such licensed product only style margin margin bottom text indent font size font family time roman harvard license notwithstanding section nbsp nbsp biogen idec acknowledges agrees that certain patent right included licensed patent harvard patent right licensed president fellow harvard college harvard pursuant amended restated license agreement between harvard dated december nbsp harvard license copy which been provided biogen idec nbsp biogen idec acknowledges agrees that right license hereunder with respect harvard patent right subject term condition harvard license without limiting style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman generality foregoing biogen idec acknowledges agrees that event termination license under section nbsp harvard license whole part termination particular country sublicense this agreement under such license shall terminate extent such terminated license except extent otherwise provided section nbsp harvard license acknowledges that solely responsible complying with obligation under harvard license style margin margin bottom text indent font size font family time roman right first negotiation style margin margin bottom text indent font size font family time roman after effective date develops developed otherwise come control know patent right outside collaboration initiate practice such know patent right part collaboration either party otherwise determines that such know patent right necessary useful biogen idec develop more licensed product that biogen idec actively developing commercializing additional intellectual property then will promptly notify biogen idec writing such additional intellectual property biogen idec will have from receipt such notice determine whether wish enter into negotiation with license under such additional intellectual property research develop manufacture sell import such applicable licensed product field other purpose biogen idec notifies writing that would like enter into negotiation such license party will negotiate good faith period reach agreement license agreement such additional intellectual property party able enter into such license agreement then party respective right obligation with regard such additional intellectual property will forth such agreement nbsp biogen idec informs that wish enter into negotiation with exclusive license under such additional intellectual property nbsp biogen idec fails provide such notice that wish enter into negotiation with exclusive license under such additional intellectual property within required period nbsp biogen idec provides notice that wish enter into negotiation with exclusive license under such additional intellectual property within required period party fail come agreement such license agreement within required period then each case will have further obligation biogen idec with regard applicable additional intellectual property except that license such additional intellectual property research develop manufacture sell import applicable licensed product term that materially favorable aggregate than those offered biogen idec final offer period additional style margin margin bottom text indent font size font family time roman notwithstanding foregoing event acquisition know patent right that subject right first negotiation forth section nbsp will include nbsp know patent right controlled acquiring style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman entity immediately prior consummation acquisition nbsp know patent right that developed acquired acquiring entity following such acquisition except such know patent right that result from acquired support collaboration style margin margin bottom text indent font size font family time roman exclusivity style margin margin bottom text indent font size font family time roman during research term thereafter except part research program neither party will conduct research development activity with respect small molecule with intended activity against target clarity either party will permitted nbsp conduct counter screening demonstrate that compound modulate target nbsp pursue small molecule program that modulates target style margin margin bottom text indent font size font family time roman addition during period starting from research term until biogen idec commences trial licensed product neither party will commence trial small molecule with intended activity against target other than another licensed product pursuant this agreement provided however that will have right time after following research term reason other than breach under section nbsp pursue research development manufacture commercialization discontinued development compound indication within excluded field subject other applicable term this agreement style margin margin bottom font size font family time roman align center patent filing prosecution maintenance enforcement style margin margin bottom text indent font size font family time roman inventorship style margin margin bottom text indent font size font family time roman inventorship inventorship invention that arise from collaboration will determined accordance with patent style margin margin bottom text indent font size font family time roman patent coordinator each party will appoint patent coordinator reasonably acceptable other party each patent coordinator serve such party primary liaison with other party matter relating filing prosecution maintenance enforcement patent right each party replace patent coordinator time notice writing other party initial patent coordinator will style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign valign bottom valign bottom janet smart style font size height height colspan style font family time roman font size valign biogen idec valign bottom valign bottom theresa devlin table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman notice inventorship each party hereby agrees promptly notify other party through patent coordinator conception reduction practice collaboration technology biogen idec collaboration technology joint collaboration technology applicable promptly execute document that necessary perfect applicable party right such collaboration technology biogen idec collaboration technology party joint right such joint collaboration technology patent coordinator will initially determine inventorship invention under patent case dispute between patent coordinator over inventorship result whether particular invention constitutes collaboration technology biogen idec collaboration technology joint collaboration technology such dispute will resolved according patent patent counsel selected patent coordinator whose firm time dispute time during five nbsp year prior such dispute performing service either party expense such patent counsel will shared equally party style margin margin bottom text indent font size font family time roman filing prosecution maintenance style margin margin bottom text indent font size font family time roman biogen idec responsibility biogen idec responsible filing prosecution maintenance biogen idec patent right joint collaboration patent right cost associated therewith style margin margin bottom text indent font size font family time roman responsibility responsible filing prosecution maintenance background patent right collaboration patent right subject harvard right with respect harvard patent right cost associated therewith notwithstanding foregoing requested biogen idec following designation lead compound will transfer responsibility biogen idec filing prosecution maintenance compound related patent right including harvard patent right extent control filing prosecution maintenance such harvard patent right under harvard agreement biogen idec will assume cost associated therewith avoidance doubt foregoing transfer right file prosecute maintain compound related patent right will impact biogen idec obligation with respect royalty payment hereunder including without limitation forth section nbsp style margin margin bottom text indent font size font family time roman information cooperation party hereby agree cooperate fully with each other matter related filing prosecution maintenance patent right under this section nbsp such cooperation will include each party nbsp reasonably consulting with other party preparation filing foreign filing prosecution correction defect maintenance licensed patent which such party responsible reasonably prior deadline action patent office which such licensed patent filed pending style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman furnishing other party with copy material filing made with respect such licensed patent reasonably advance consultation thereon nbsp reasonably discussing good faith comment suggestion made other party course such consultation extent such comment reasonable made other party timely manner each party affiliate hereby agree promptly supply execute paper instrument require their respective employee supply execute such paper instrument necessary appropriate purpose preparing filing prosecuting maintaining licensed patent promptly inform prosecuting party matter that expected reasonably affect preparation filing prosecution maintenance validity enforceability licensed patent style margin margin bottom text indent font size font family time roman patent term extension supplemental protection certificate will appoint biogen idec designee agent sole purpose submitting application extend term licensed patent including harvard patent right subject section nbsp harvard license country which biogen idec designee will have secured regulatory approval marketing sale licensed product covered such patent right hereby agrees reasonably cooperate with biogen idec designee matter relating such application patent term extension supplemental protection certificate further compound related patent right including harvard patent right subject section nbsp harvard license biogen idec will have sole right decide whether such patent right extended style margin margin bottom text indent font size font family time roman cost sharing with respect prosecution patent right party responsible cost filing prosecution maintenance patent right including defense prosecution interference derivation opposition reexamination reissue inter partes review post grant review under section will entitled include such cost sharing party accordance with section nbsp exhibit extent such cost relate development compound developed licensed product style margin margin bottom text indent font size font family time roman interference derivation opposition reexamination reissue style margin margin bottom text indent font size font family time roman notice more than thirty nbsp following discovery either party request filing declaration interference derivation opposition reexamination proceeding inter partes review post grant review with respect licensed patent biogen idec patent determination either party that licensed patent biogen idec patent should reissued avert invalidity unenforceability thereof permissibly broaden such licensed patent biogen idec patent discovering determining party will notify other party such event style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman primary responsibility cooperation biogen idec will have primary responsibility expense undertaking course action defend prosecute such interference derivation opposition reexamination reissue inter partes review post grant review with respect biogen idec patent right joint collaboration patent right will have primary responsibility expense undertaking course action defend prosecute such interference derivation opposition reexamination reissue inter partes review post grant review with respect background patent right collaboration patent right subject harvard right with respect harvard patent right notwithstanding foregoing compound related patent right biogen idec will have right defend prosecute such interference derivation opposition reexamination reissue inter partes review post grant review expense requested biogen idec writing timely manner subject harvard right under section nbsp harvard license modified section nbsp harvard license with respect harvard patent right applicable party will cooperate fully with each other each will provide other information assistance that other reasonably request with respect course action taken under this section nbsp responsible party will nbsp keep other party reasonably informed development such interference derivation opposition reexamination reissue including extent permissible status settlement negotiation term offer related thereto nbsp provide other party with copy submission agreement arising connection with such proceeding sufficiently advance their filing date execution date give other party sufficient time comment thereon nbsp give good faith consideration other party comment each party respective affiliate hereby agree promptly supply execute paper instrument require their respective employee supply execute such paper instrument necessary appropriate purpose assisting responsible party course action taken under this section nbsp promptly inform responsible party matter that other party reasonable judgment affect course action taken under this section nbsp style margin margin bottom text indent font size font family time roman decision file abandonment party decides prepare file patent application with respect licensed patent including joint collaboration patent right anywhere territory cease prosecution allow lapse such patent right such country region such party abandoning party will inform other party such decision promptly order provide such other party reasonable amount time meet applicable deadline establish preserve such patent right such country region subject harvard right under harvard license with respect harvard patent right such other party will have right obligation assume responsibility continuing prosecution such patent right such country region paying required maintain such patent right such country region defending such patent right such party exercise such right assuming party assuming party sole expense through style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman patent counsel agent choice provided that assuming party will take position with respect such abandoned patent right that will reasonably likely adversely affect scope validity enforceability other patent right being prosecuted maintained abandoning party pursuant section nbsp case without prior written consent abandoning party which consent will unreasonably withheld assuming party will become assignee such patent right result assumption such responsibility event that biogen idec becomes assuming party with respect such patent right further royalty payment will hereunder from biogen idec connection with such patent right country country which they were abandoned provided that royalty payment otherwise hereunder will affected event that becomes assuming party with respect such patent right biogen idec will longer have license practice such patent right hereunder country country which they were abandoned upon transfer abandoning party responsibility filing prosecuting maintaining such patent right assuming party under this section nbsp nbsp abandoning party will nbsp promptly deliver assuming party copy necessary file related such patent right with respect which responsibility been transferred nbsp take action execute document reasonably necessary assuming party assume such prosecution maintenance nbsp assuming party will thereafter solely responsible filing prosecution maintenance defense such patent right sole expense commencing date which notified abandoning party decision assume such responsibility assuming party will obliged reimburse abandoning party patent related cost incurred prior date such decision assuming party thereafter elect abandon such patent right without requirement notice other party style margin margin bottom text indent font size font family time roman enforcement against third party infringement style margin margin bottom text indent font size font family time roman notice event either party nbsp becomes aware suspected infringement misappropriation licensed patent including joint collaboration patent right anywhere territory that cover development commercialization development compound licensed product field nbsp receives application submission notice under certification that comparable paragraph patent certification third party filing abbreviated drug application filing application under other similar patent certification third party each case that comprises incorporates otherwise affect licensed product each infringement that party will promptly notify other party provide with detail such infringement which aware each infringement notice patent coordinator will promptly meet discus infringement strategy patent enforcement with respect such infringement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman biogen idec right subject section nbsp infringement action invalidate relates licensed patent biogen idec patent right including joint collaboration patent right biogen idec will have first right obligation address such infringement territory taking reasonable step which include institution legal proceeding other action each action compromise settle such action provided that nbsp biogen idec will keep reasonably informed about such action will consult with before taking major step during conduct such action nbsp will provide reasonable cooperation biogen idec connection with such action including extent action involves licensed patent including limited joint collaboration patent right promptly supplying executing paper instrument requiring their respective employee supply execute such paper instrument necessary purpose initiating pursuing such action nbsp biogen idec will take position with respect compromise settle such action nbsp that will reasonably likely reduce royalty term major market country otherwise materially adversely impact royalty rate payable such major market country without prior written consent which unreasonably withheld conditioned delayed nbsp with respect harvard patent right subject harvard right under section nbsp harvard license nbsp biogen idec determines institute action with respect infringement determines cease pursue such action will promptly inform section nbsp will apply biogen idec will incur liability consequence such action unfavorable decision resulting therefrom including decision holding such claim invalid infringed unenforceable cost including without limitation attorney relating such action will borne solely biogen idec style margin margin bottom text indent font size font family time roman right style margin margin bottom text indent font size font family time roman nbsp biogen idec informs that intend prosecute action respect licensed patent including joint collaboration patent right anywhere territory pursuant section nbsp nbsp biogen idec commenced action within after infringement notice nbsp biogen idec determines cease pursue such action with respect such infringement then will have right upon notice biogen idec take appropriate action address such infringement including initiating action taking over prosecution action initiated biogen idec provided that such event nbsp will keep biogen idec reasonably informed about such action will consult with biogen idec before taking major step during conduct such action nbsp biogen idec will provide reasonable cooperation connection with such action including extent action involves joint collaboration patent right promptly supplying executing paper instrument requiring their respective employee supply execute such paper instrument necessary purpose initiating style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman pursuing such action nbsp will take position with respect compromise settle such action that reasonably likely directly adversely affect scope validity enforceability licensed patent without biogen idec prior written consent which withheld biogen idec sole discretion notwithstanding foregoing will without biogen idec prior written consent entitled take over initiate action with respect such infringement that involves compound related patent right enforcement against such infringement would reasonably likely directly adversely affect scope validity enforceability compound related patent right which consent granted withheld biogen idec sole discretion will incur liability biogen idec consequence such action unfavorable decision resulting therefrom including decision holding such claim invalid infringed unenforceable cost including without limitation attorney relating such action that arise after such action assumed will borne solely style margin margin bottom text indent font size font family time roman notwithstanding anything contrary section researching developing commercializing discontinued development compound product containing same then will have right enforce patent right that included licensed patent against infringement with respect product that competitive with such discontinued development compound will responsible cost associated therewith notwithstanding foregoing will able enforce against such infringement without biogen idec consent compound related patent right such consent unreasonably withheld biogen idec unless enforcement against such infringement would reasonably likely directly adversely affect scope validity enforceability such compound related patent right which case such consent granted withheld biogen idec sole discretion style margin margin bottom text indent font size font family time roman right representation each party will have right participate represented counsel that selects action instituted under section nbsp applicable other party party with right initiate action under section nbsp applicable eliminate infringement lack standing other party standing initiate such action then party with right initiate action under section nbsp applicable name other party plaintiff such action require party with standing initiate such action expense other party provided that party with right initiate action agrees indemnify other party liability expense including without limitation reasonable attorney other expense litigation incurred such other party result such action style margin margin bottom text indent font size font family time roman cooperation action instituted under this section nbsp party will cooperate with assist each other reasonable respect style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman allocation proceeds subject harvard right under harvard license with respect harvard patent amount recovered either party pursuant action under this section nbsp whether settlement judgment will after reimbursing biogen idec their respective reasonable pocket expense incurred pursuing such action obtaining such recovery which amount will allocated insufficient cover totality such expense retained paid biogen idec treated nbsp extent infringement relates sole licensed product sale sole licensed product affected infringement purpose this agreement with respect such that biogen idec will applicable royalty such sale pursuant section nbsp nbsp extent infringement relates developed licensed product revenue generated such developed licensed product which will shared party accordance with section nbsp exhibit without limiting foregoing extent amount recovered either party pursuant such action pursuant term more license sublicense agreement entered into such party such third party infringer amount paid such third party under such agreement will treated they were amount recovered settlement judgment style margin margin bottom text indent font size font family time roman defense claim style margin margin bottom text indent font size font family time roman notice event that action suit proceeding brought against either party affiliate either party sublicensee distributor biogen idec alleging infringement technology patent right third party reason development commercialization licensed product behalf biogen idec affiliate sublicensees distributor such party will notify other party promptly possible following receipt service process such action suit proceeding date such party becomes aware that such action suit proceeding been instituted patent coordinator will meet soon possible discus overall strategy defense such matter style margin margin bottom text indent font size font family time roman biogen idec obligation unless otherwise mutually agreed party subject section nbsp nbsp biogen idec will have right obligation defend such action suit proceeding sole expense nbsp affiliate will have right separate counsel expense such action suit proceeding nbsp party will cooperate with each other reasonable respect such action suit proceeding nbsp expense with respect such action suit proceeding territory will borne solely biogen idec style margin margin bottom text indent font size font family time roman cooperation each party will promptly furnish other party with copy each communication relating alleged infringement that received such party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman including document filed litigation event will either party settle otherwise resolve such action suit proceeding brought against other party affiliate sublicensees without other party prior written consent unreasonably withheld style margin margin bottom font size font family time roman align center confidential information publicity publication style margin margin bottom text indent font size font family time roman confidentiality style margin margin bottom text indent font size font family time roman each party agrees that will maintain confidential information disclosed other party strict confidence during term this agreement period five nbsp year after expiration termination this agreement except that each party disclose permit disclosure such confidential information director officer employee consultant collaborator advisor including legal counsel obliged maintain confidential nature such confidential information need know such confidential information purpose this agreement each party will such confidential information only purpose this agreement allow director officer employee consultant collaborator advisor reproduce such confidential information only extent necessary purpose this agreement with such reproduction being deemed confidential information style margin margin bottom text indent font size font family time roman exception confidentiality obligation each receiving party imposed section nbsp will apply confidential information disclosed receiving party disclosing party which nbsp known receiving party prior effective date other than result disclosure under other agreement between party demonstrated documentary evidence nbsp becomes generally available public through mean other than unauthorized disclosure receiving party nbsp subsequently disclosed receiving party third party having bona fide right disclose such confidential information without breaching obligation disclosing party nbsp developed independently receiving party without benefit recourse disclosing party confidential information demonstrated documentary evidence nbsp published pursuant section nbsp addition receiving party make disclosure confidential information disclosing party extent required comply with applicable regulation court administrative order provided that receiving party provides disclosing party with reasonable prior written notice nbsp take reasonable lawful action assist disclosing party obtaining confidential treatment such disclosure nbsp discloses minimum amount scope disclosing party confidential information necessary comply with applicable regulation order style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman permitted disclosure notwithstanding anything contrary this section nbsp each receiving party will have right disclose confidential information disclosing party following person nbsp patent office country which patent right sought purpose prosecuting application patent right defending patent right interference opposition action provided that such disclosure will made only after notifying disclosing party accordance with section nbsp nbsp regulatory authority necessary pursue development commercialization regulatory approval licensed product nbsp such party affiliate collaborator consultant other service provider case biogen idec distributor sublicensees each case need know such confidential information development commercialization regulatory approval licensed product provided that each case such person bound obligation confidentiality consistent with term this agreement style margin margin bottom text indent font size font family time roman disclosure term agreement publicity subject final sentence this section nbsp neither party will issue press news release make similar public announcement related execution term this agreement conduct development program commercialization licensed product without prior written consent other party provided that either party make such disclosure nbsp extent required applicable regulation including requirement nationally recognized security exchange quotation system over counter market which such party security listed traded nbsp acquirors prospective acquirors investor prospective investor lender other potential financing source attorney accountant other advisor such person each case obligated keep such information confidential event that such disclosure required pursuant subsection disclosing party will provide other party with written notice beforehand coordinate with other party with respect wording timing such disclosure cooperate with other party maintain confidential treatment material term this agreement extent reasonably possible party upon execution this agreement shall jointly issue press release with respect this agreement form mutually agreed party either party make subsequent public disclosure content such press release without further approval other party thereafter where request public disclosure made party with respect this agreement party will agree upon form press release other public statement either party make subsequent public disclosure content such press release other public statement provided that disclosing party will depart from agreed upon form without prior written consent other party style margin margin bottom text indent font size font family time roman name neither party will name other party promotional material advertising without prior express written permission other party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman publication presentation style margin margin bottom text indent font size font family time roman right review delay publication subject paragraph nbsp nbsp this section nbsp during research term each party publishing party will submit other party reviewing party prior review proposed academic scientific medical publication public presentation that relates activity contemplated under this agreement compound such review will conducted purpose preserving value licensed technology biogen idec technology joint collaboration technology right granted hereunder determining whether portion proposed publication presentation should modified deleted furtherance such purpose written copy such proposed publication presentation required submitted hereunder will submitted reviewing party nbsp later than before submission poster paper presented conference nbsp later than before submission other publication presentation either case notice period reviewing party will provide comment with respect such publication presentation within receipt such written copy provided that such review period extended additional event reviewing party determines sole discretion that such extension necessary preparation filing patent application allow party agree modification publication disclose reviewing party confidential information either case delay period upon expiration notice period publishing party shall free proceed with written publication oral presentation unless reviewing party requested delay described above which case publishing party shall free proceed with written publication oral presentation with agreed upon modification only upon expiration delay period unless sooner authorized reviewing party publishing party will comply with standard academic practice regarding authorship scientific publication recognition contribution other party publication addition procedure forth this section nbsp will also apply proposed academic scientific medical publication public presentation after research term that relates development compound licensed product which engaged development commercialization style margin margin bottom text indent font size font family time roman after research term developing commercializing after research term engaged development commercialization particular development compound licensed product hereunder biogen idec will lieu obligation under section nbsp commercially reasonable effort provide with copy proposed public disclosure relating such development compound licensed product reasonably advance disclosure including through publication discussion scientific material written electronic oral otherwise consider good faith reasonable comment provided subject foregoing biogen idec style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman affiliate third party authorized biogen idec nbsp make such public disclosure deems appropriate connection with development commercialization licensed product under this agreement nbsp publish have published information about clinical trial related licensed product including result such clinical trial avoidance doubt after research term without biogen idec prior written consent make academic scientific medical publication public presentation that relates compound lead compound development compound back compound licensed product which engaged development commercialization style margin margin bottom text indent font size font family time roman discontinued collaboration compound after research term will commercially reasonable effort provide biogen idec with copy proposed public disclosure relating discontinued collaboration compound reasonably advance disclosure including through publication discussion scientific material written electronic oral otherwise consider good faith reasonable comment provided biogen idec subject foregoing shall free nbsp make public disclosure deems appropriate with respect discontinued collaboration compound nbsp publish have published information about clinical trial related discontinued collaboration compound product containing same including result such clinical trial style margin margin bottom font size font family time roman align center representation warranty style margin margin bottom text indent font size font family time roman mutual representation warranty biogen idec each hereby represents warrant other follows style margin margin bottom text indent font size font family time roman organization corporation duly organized validly existing good standing under jurisdiction organization requisite power authority corporate otherwise execute deliver perform this agreement style margin margin bottom text indent font size font family time roman authorization execution delivery this agreement performance transaction contemplated hereby have been duly authorized necessary corporate action will violate nbsp such party certificate incorporation bylaw equivalent charter organizational document nbsp agreement instrument contractual obligation which such party bound nbsp requirement applicable regulation court administrative under nbsp order writ judgment injunction decree determination award court governmental agency presently effect applicable such party style margin margin bottom text indent font size font family time roman binding agreement this agreement legal valid binding obligation such party enforceable against accordance with term condition style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman inconsistent obligation under obligation contractual otherwise person that conflict with inconsistent respect with term this agreement that will impede diligent complete fulfillment obligation hereunder style margin margin bottom text indent font size font family time roman government authorization required government authorization consent approval license exemption filing registration with court governmental department commission board bureau agency instrumentality domestic foreign under applicable regulation currently effect will necessary connection with transaction contemplated this agreement performance obligation under this agreement style margin margin bottom text indent font size font family time roman compliance with such party will comply will cause sublicensees their affiliate comply with local state international regulation relating development manufacture sale importation licensed product licensed technology material provided other party hereunder without limiting foregoing such party will comply will cause sublicensees their affiliate comply with united state export control regulation applicable licensed product such material style margin margin bottom text indent font size font family time roman debarment neither such party affiliate such party been debarred under generic drug enforcement under investigation debarment action been disqualified investigator pursuant disqualification hearing pending currently employing using person that been debarred disqualified perform such party obligation under this agreement each party will promptly notify other party employee contractor agent debarred disqualified described this section nbsp will terminate debarred disqualified individual entity participation performance such affected party obligation under this agreement promptly upon awareness such debarment disqualification style margin margin bottom text indent font size font family time roman additional representation further represents warrant biogen idec follows style margin margin bottom text indent font size font family time roman ownership control control licensed technology existence effective date except patent right within licensed technology existence effective date that controlled under third party agreement sublicensed biogen idec sole exclusive owner solely control licensed technology existence effective date other person claim ownership with respect such licensed technology previously assigned style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman transferred conveyed otherwise encumbered right title interest licensed technology manner inconsistent with right license granted biogen idec under this agreement style margin margin bottom text indent font size font family time roman third party agreement listed exhibit agreement existing effective date between third party pursuant which right obligation with respect licensed technology third party agreement will keep full force effect throughout term term third party agreement that relevant right sublicensed biogen idec under this agreement style margin margin bottom text indent font size font family time roman data patent right know effective date there information provided biogen idec pursuant this agreement that untrue inaccurate there information that failed provide pursuant this agreement that necessary make information provided biogen idec pursuant this agreement complete misleading filing licensed patent other than harvard patent right that exist effective date have been made compliance with applicable requirement knowledge harvard patent right that exist effective date have been made compliance with applicable requirement disclosed biogen idec licensed technology controlled effective date style margin margin bottom text indent font size font family time roman validity licensed patent knowledge nbsp background patent right existing nbsp issued patent which part background patent right invalid unenforceable style margin margin bottom text indent font size font family time roman diligent prosecution maintenance licensed patent that exist effective date have been diligently prosecuted with respective patent office accordance with applicable necessary maintain such licensed patent have been paid before date such payment style margin margin bottom text indent font size font family time roman interference knowledge nbsp licensed patent that exist effective date subject interference proceeding nbsp there pending threatened action suit proceeding claim third party challenging ownership right validity scope such licensed patent style margin margin bottom text indent font size font family time roman claim knowledge nbsp there claim judgment settlement against pending threatened that invalidate seek invalidate licensed patent that exist effective date nbsp there opposition pending jurisdiction outside united state that challenge validity enforceability such licensed patent that jurisdiction nbsp there litigation pending against affiliate that alleges that activity contemplated this agreement will violate intellectual property right third party received written communication threatening such litigation style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman infringement knowledge practice background patent right background know contemplated this agreement will infringe misappropriate valid enforceable third party patent right that exist effective date style margin margin bottom text indent font size font family time roman government funding received funding from governmental authority with respect licensed technology that exists effective date avoidance doubt biogen idec acknowledges that harvard received such funding with respect harvard patent right style margin margin bottom text indent font size font family time roman invention assignment each individual inventor otherwise contributed material manner creation development licensed patent existence effective date assigned interest therein knowledge case harvard patent right assigned harvard interest therein style margin margin bottom text indent font size font family time roman covenant covenant biogen idec follows style margin margin bottom text indent font size font family time roman ownership control after effective date will continue control licensed technology except patent right within licensed technology that controlled under third party agreement sublicensed biogen idec will continue sole exclusive owner solely control licensed technology that exists effective date after effective date will promptly inform biogen idec person asserts against claim ownership with respect such licensed technology style margin margin bottom text indent font size font family time roman filing licensed patent after effective date subject right under section nbsp nbsp will make filing those licensed patent over which control prosecution nbsp shall take reasonable step accordance with right under harvard license ensure that harvard make filing those licensed patent over which harvard control prosecution each case compliance with applicable requirement style margin margin bottom text indent font size font family time roman validity licensed patent after effective date subject right under section nbsp will take reasonable step nbsp prevent licensed patent over which control prosecution from ceasing exist becoming invalid unenforceable nbsp accordance with right under harvard license prevent harvard from allowing licensed patent over which harvard control prosecution from ceasing exist becoming invalid unenforceable style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman diligent prosecution maintenance after effective date subject right under section nbsp will nbsp continue diligently prosecute those licensed patent over which control prosecution including paying necessary maintain such licensed patent before date such payment nbsp take reasonable step accordance with right under harvard license cause harvard diligently prosecute those licensed patent over which harvard control prosecution each case with respective patent office accordance with applicable including paying necessary maintain such licensed patent before date such payment style margin margin bottom text indent font size font family time roman ownership challenge after effective date subject right under section nbsp will promptly inform biogen idec knowledge threatened action suit proceeding claim asserted third party challenging harvard other third party licensor ownership right licensed patent style margin margin bottom text indent font size font family time roman claim after effective date subject right under section nbsp will promptly inform biogen idec knowledge nbsp claim judgment settlement against harvard other third party licensor become pending threatened that invalidate seek invalidate licensed patent nbsp opposition becomes pending jurisdiction outside united state that challenge validity enforceability licensed patent that jurisdiction nbsp litigation becomes pending against affiliate harvard other third party licensor that alleges that activity contemplated this agreement will violate intellectual property right third party receive written communication threatening such litigation style margin margin bottom text indent font size font family time roman government funding after effective date will receive accept funding from governmental authority with respect licensed technology including sbir grant without biogen idec prior written consent foregoing covenant will apply such funding that support research development commercialization discontinued collaboration compound long such funding diminish encumber biogen idec right hereunder licensed technology with respect licensed product development compound back compound style margin margin bottom text indent font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman covenant biogen idec biogen idec covenant follows style margin margin bottom text indent font size font family time roman control after effective date biogen idec will continue control biogen idec technology style margin margin bottom text indent font size font family time roman filing biogen idec patent right licensed patent after effective date subject right under section nbsp biogen idec will make filing biogen idec patent right those licensed patent over which control prosecution compliance with applicable requirement style margin margin bottom text indent font size font family time roman validity biogen idec patent licensed patent after effective date subject right under section nbsp biogen idec will take reasonable step prevent biogen idec patent right those licensed patent over which control prosecution from ceasing exist becoming invalid unenforceable style margin margin bottom text indent font size font family time roman diligent prosecution maintenance after effective date subject right under section nbsp biogen idec will continue diligently prosecute biogen idec patent right those licensed patent over which biogen idec control prosecution with respective patent office accordance with applicable including paying necessary maintain such patent right before date such payment style margin margin bottom text indent font size font family time roman ownership challenge after effective date subject right under section nbsp biogen idec will promptly inform biogen idec knowledge threatened action suit proceeding claim asserted third party challenging biogen idec third party licensor ownership right biogen idec patent right style margin margin bottom text indent font size font family time roman claim after effective date subject right under section nbsp biogen idec will inform biogen idec knowledge nbsp claim judgment settlement against biogen idec third party licensor become pending threatened that invalidate seek invalidate biogen idec patent right licensed patent over which biogen idec control prosecution nbsp opposition becomes pending jurisdiction outside united state that challenge validity enforceability such biogen idec patent right licensed patent that jurisdiction nbsp litigation becomes pending against biogen idec affiliate biogen idec third party licensor that alleges that activity contemplated this agreement will violate intellectual property right third party biogen idec receives written communication threatening such litigation style margin margin bottom text indent font size font family time roman government funding after effective date biogen idec will receive funding from governmental authority with respect research development licensed technology biogen idec technology without prior written consent style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman warranty disclaimer representation warranty made either party other than expressly forth this section particular each party disclaims following warranty whether express implied whether licensed product developed marketed successfully regarding commercial value licensed product merchantability fitness particular purpose licensed product whether patent right obtained maintained licensed product whether manufacture marketing sale licensed product will constitute infringement intellectual property right third party style margin margin bottom font size font family time roman align center indemnification insurance style margin margin bottom text indent font size font family time roman indemnification biogen idec biogen idec will defend indemnify hold harmless affiliate their respective employee officer director agent indemnitees from against liability damage loss cost expense nature including reasonable attorney litigation expense incurred imposed upon indemnitees them connection with claim suit action demand proceeding cause action judgment resulting from third party claim arising nbsp development design testing production manufacture importation offer sale sale promotion development compound back compound licensed product biogen idec affiliate sublicensees distributor nbsp breach biogen idec term this agreement nbsp gross negligence willful misconduct biogen idec employee agent officer director except each case extent that such claim result arises from matter which obligated indemnify biogen idec under section style margin margin bottom text indent font size font family time roman indemnification biogen idec will defend indemnify hold harmless biogen idec affiliate their respective employee officer director agent biogen idec indemnitees from against liability damage loss cost expense nature including reasonable attorney litigation expense incurred imposed upon biogen idec indemnitees them connection with claim suit action demand proceeding cause action judgment resulting from third party claim arising nbsp breach term this agreement nbsp gross negligence willful misconduct employee agent officer director nbsp extent such liability damage loss cost expense arises matter that occurred during period when party developing more development compound licensed style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman product under section nbsp commercializing more development compound licensed product under section nbsp development design testing production manufacture importation offer sale sale promotion such development compound licensed product affiliate sublicensees distributor except each case extent that such claim result arises from matter which biogen idec obligated indemnify under section nbsp style margin margin bottom text indent font size font family time roman condition indemnification person seeking indemnification indemnitee under this section nbsp will give prompt written notice indemnity claim indemnifying party provide copy indemnifying party complaint summons other written verbal notice that indemnitee receives connection with such claim indemnitee failure deliver written notice will relieve indemnifying party liability indemnitee under this section nbsp only extent such delay prejudicial indemnifying party ability defend such claim provided that indemnifying party contesting indemnity obligation indemnitee will permit indemnifying party control litigation relating such claim disposition such claim negotiated settlement otherwise indemnifying party shall assume such control with counsel mutually satisfactory party indemnifying party will reasonably good faith with respect matter relating such claim will settle otherwise resolve such claim without indemnitees prior written consent which will withheld delayed unreasonably indemnitees will cooperate with indemnifying party such party defense claim which indemnity sought under this agreement indemnifying party sole cost expense style margin margin bottom text indent font size font family time roman limited liability except such damage arising party breach obligation under section neither party will liable other party affiliate special punitive indirect incidental consequential damage including without limitation lost profit lost revenue whether under contract warranty negligence strict liability other legal equitable theory nothing this section will limit either party obligation under section applicable style margin margin bottom text indent font size font family time roman insurance style margin margin bottom text indent font size font family time roman insurance obligation will maintain cost reasonable insurance against liability other risk associated with activity contemplated this agreement provided that engaged development development compound back compound licensed product hereunder will maintain force from thirty nbsp prior enrollment first subject clinical trial clinical trial product liability style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman insurance policy providing coverage least claim annually aggregate provided further that exercise commercialization option that such coverage increased least least thirty nbsp before biogen idec initiate first commercial sale applicable licensed product will furnish biogen idec evidence such insurance upon request style margin margin bottom text indent font size font family time roman biogen idec insurance obligation biogen idec together with affiliate will maintain cost reasonable insurance against liability other risk associated with activity contemplated this agreement provided that minimum biogen idec will maintain force from thirty nbsp prior enrollment first subject clinical trial clinical trial product liability insurance policy providing coverage least claim annually aggregate provided further that such coverage increased least least thirty nbsp before biogen idec initiate first commercial sale licensed product biogen idec will furnish evidence such insurance upon request notwithstanding foregoing biogen idec self insure extent that self insures other product minimum will self insure level that consistent with level customarily maintained against similar risk similar company biogen idec industry style margin margin bottom font size font family time roman align center term termination style margin margin bottom text indent font size font family time roman term this agreement will commence effective date will continue full force effect unless otherwise terminated pursuant section nbsp until expiration applicable royalty term with respect licensed product country territory term upon expiration this agreement forth this section nbsp license right granted hereunder will converted perpetual fully paid license with right grant unlimited sublicenses style margin margin bottom text indent font size font family time roman termination this agreement terminated follows style margin margin bottom text indent font size font family time roman research term research term this agreement will terminate automatically biogen idec designated least nbsp development compound unless nbsp party have previously mutually agreed activity aimed advancing lead compound designation development compound mutually agreed plan such activity extends beyond research term nbsp party mutually agree least prior expiration research term continue research specified additional period time agree relevant matter relating such extension including limited party respective right obligation with regard ongoing research budget such ongoing research party respective monetary obligation with regard such budget style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman unilateral right terminate agreement biogen idec terminate this agreement style margin margin bottom text indent font size font family time roman during research term nbsp vivo target validation milestone been achieved within after effective date nbsp least lead compound development candidate criterion within after effective date style margin margin bottom text indent font size font family time roman following research term licensed product licensed product basis time sole discretion effective sixty nbsp after providing written notice biogen idec terminated this agreement with respect licensed product this agreement will terminate entirety style margin margin bottom text indent font size font family time roman termination breach addition other remedy available equity either party will have right terminate this agreement event material breach other party provided that other party fails cure such material breach within sixty nbsp after written notice thereof received from breaching party style margin margin bottom text indent font size font family time roman termination bankruptcy style margin margin bottom text indent font size font family time roman this agreement terminated party bankrupt party upon filing institution bankruptcy reorganization liquidation receivership proceeding upon assignment substantial portion asset benefit creditor other party bankrupt party provided however that event involuntary bankruptcy receivership proceeding such right terminate will only become effective bankrupt party consent involuntary bankruptcy receivership such proceeding dismissed within sixty nbsp after filing such bankruptcy receivership style margin margin bottom text indent font size font family time roman license right license granted under pursuant this agreement bankrupt party bankrupt party will otherwise deemed purpose section nbsp united state bankruptcy code bankruptcy code license right intellectual property defined under section nbsp bankruptcy code party agree that bankrupt party licensee such right under this agreement will retain fully exercise right election under bankruptcy code party further agree that upon commencement bankruptcy proceeding against bankrupt party under bankruptcy code bankrupt party will entitled complete duplicate complete access bankrupt party deems appropriate style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman such intellectual property embodiment such intellectual property such intellectual property embodiment such intellectual property will promptly delivered bankrupt party nbsp upon such commencement bankruptcy proceeding upon written request bankrupt party unless bankrupt party elect continue perform obligation under this agreement nbsp delivered under nbsp above upon rejection this agreement behalf bankrupt party upon written request bankrupt party bankrupt party capacity including debtor possession successor assigns including trustee agrees interfere with exercise bankrupt party affiliate right license such intellectual property such embodiment intellectual property accordance with this agreement agrees assist bankrupt party affiliate obtaining such intellectual property such embodiment intellectual property possession control third party reasonably necessary desirable bankrupt party exercise such right license accordance with this agreement foregoing provision without prejudice right bankrupt party have arising under bankruptcy code other applicable style margin margin bottom text indent font size font family time roman effect termination event termination this agreement pursuant section nbsp following provision will apply applicable style margin margin bottom text indent font size font family time roman termination under section nbsp biogen idec under section nbsp this agreement terminates under section nbsp terminated biogen idec under section nbsp then style margin margin bottom text indent font size font family time roman license granted either party other party under this agreement will terminate right with respect intellectual property right licensed will revert party that owns affected intellectual property right style margin margin bottom text indent font size font family time roman exclusivity restriction forth section nbsp will terminate each party each party will free research develop commercialize product that modulate target either themselves with third party subject intellectual property right other party style margin margin bottom text indent font size font family time roman termination biogen idec under section nbsp biogen idec terminates right with regard more licensed product under section nbsp then style margin margin bottom text indent font size font family time roman license granted biogen idec that relate terminated licensed product corresponding development compound back compound will terminate except with respect back compound that have nbsp also nbsp been designated back compound terminated licensed product development compound license nbsp granted biogen idec that relate terminated licensed product corresponding development compound back compound will remain full force effect style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman biogen idec will grant perpetual irrevocable royalty free fully paid exclusive license with right sublicense under biogen idec technology including biogen idec interest joint collaboration technology make have made sell offer sell have sold import otherwise exploit field royalty free product which biogen idec exercised right terminate under section nbsp which license will limited restriction forth first sentence section nbsp will otherwise subject term such section nbsp such royalty free product discontinued collaboration compound related product style margin margin bottom text indent font size font family time roman biogen idec will negotiate good faith grant royalty bearing license field with nbsp respect licensed biogen idec proprietary compound corresponding development compound back compound which biogen idec exercised right terminate under section nbsp provided that nbsp avoidance doubt party agree term license such licensed biogen idec proprietary compound nbsp within after biogen idec exercised right terminate such licensed biogen idec proprietary compound nbsp under section nbsp then biogen idec obligation negotiate such license shall cease style margin margin bottom text indent font size font family time roman biogen idec will assign regulatory filing clinical data relating licensed product which biogen idec granting license under this section nbsp style margin margin bottom text indent font size font family time roman request period exceed provide commercially reasonable assistance expense necessary permit develop commercialize royalty free product licensed biogen idec proprietary compound which biogen idec granting license under this section nbsp including disclosing making available relevant biogen idec technology transitioning information described section nbsp style margin margin bottom text indent font size font family time roman will released from exclusivity provision section nbsp provided however that biogen idec terminated with respect more licensed product then such release shall solely extent necessary permit exercise license granted under this section nbsp style margin margin bottom text indent font size font family time roman termination under section this agreement terminated under section then style margin margin bottom text indent font size font family time roman license granted biogen idec will terminate style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman will released from exclusivity restriction forth section nbsp style margin margin bottom text indent font size font family time roman biogen idec will grant perpetual irrevocable royalty free fully paid exclusive license with right sublicense under biogen idec technology biogen idec interest joint collaboration technology make have made sell offer sell have sold import otherwise exploit field royalty free product which license will limited restriction forth first sentence section nbsp will otherwise subject term such section nbsp such royalty free product discontinued collaboration compound related product style margin margin bottom text indent font size font family time roman biogen idec will negotiate good faith grant royalty bearing license field with respect licensed biogen idec proprietary compound provided that avoidance doubt party agree term license licensed biogen idec proprietary compound within after termination this agreement then biogen idec obligation negotiate such license shall cease style margin margin bottom text indent font size font family time roman biogen idec will assign regulatory filing clinical data relating licensed product which biogen idec granting license under this section nbsp style margin margin bottom text indent font size font family time roman request period exceed biogen idec will provide commercially reasonable assistance expense necessary permit develop commercialize royalty free product licensed biogen idec proprietary compound which biogen idec granting license under this section nbsp including disclosing making available relevant biogen idec technology transitioning information described section nbsp style margin margin bottom text indent font size font family time roman termination biogen idec under section this agreement terminated biogen idec under section then style margin margin bottom text indent font size font family time roman license granted biogen idec will terminate style margin margin bottom text indent font size font family time roman license granted biogen idec will survive such termination style margin margin bottom text indent font size font family time roman development commercialization will cease development compound will become sole development compound developed style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman licensed product commercialized licensed product will become sole licensed product will reasonably assist biogen idec period more than transferring biogen idec material information necessary biogen idec continue research development commercialization licensed product style margin margin bottom text indent font size font family time roman biogen idec will released from exclusivity restriction forth section nbsp will free research develop commercialize product that modulate target either itself with collaborator provided that biogen idec continues commercially reasonable effort develop commercialize such licensed product amount hereunder during term that would otherwise payable provided further that royalty rate payable biogen idec will reduced from rate forth section nbsp style margin margin bottom text indent font size font family time roman confidential information upon termination this agreement reason receiving party will destroy written electronic other material containing confidential information disclosing party provided disclosing party connection with this agreement including copy thereof within such termination provide certification such destruction disclosing party provided that nbsp receiving party retain copy archive solely purpose monitoring ongoing confidentiality obligation hereunder nbsp receiving party will obligated destroy such material containing confidential information disclosing party that necessary useful receiving party exercise license right receiving party that survives such termination this agreement provided that receiving party such confidential information disclosing party will continue subject requirement restriction forth section nbsp style margin margin bottom text indent font size font family time roman sublicenses license granted biogen idec under this agreement terminated sublicenses hereunder that were granted biogen idec prior termination effect immediately prior termination will remain full force effect provided that nbsp sublicensee then breach sublicense agreement nbsp sublicensee agrees bound licensor under term condition sublicense agreement nbsp will deemed have assumed obligation under such sublicense agreement that broader scope than those under this agreement subject foregoing will enter into appropriate agreement amendment sublicense agreement substitute itself biogen idec licensor thereunder style margin margin bottom text indent font size font family time roman surviving provision following provision will survive expiration termination this agreement period time specified therein specified then they will survive indefinitely section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom margin right font size font family time roman except section nbsp addition nbsp other term this agreement will survive solely necessary fulfill applicable nbsp provision section nbsp nbsp termination this agreement will relieve party liability that accrued hereunder nbsp prior effective date such termination preclude either party from pursuing right remedy have nbsp hereunder nbsp equity with respect breach this agreement without limiting generality clause nbsp nbsp immediately preceding sentence avoidance doubt upon termination this agreement pursuant which applicable provision section nbsp provide that nbsp biogen idec retains some license right section nbsp with respect summary report only with respect summary report only through nbsp through nbsp shall also survive such termination nbsp retains some license right section shall also survive such termination remedy provided this section nbsp exclusive other remedy party have equity style margin margin bottom font size font family time roman align center miscellaneous style margin margin bottom text indent font size font family time roman change control program sale style margin margin bottom text indent font size font family time roman notice will provide biogen idec with reasonably prompt written notice intent undergo change control effect program sale prior consummating either such transaction each sale notice style margin margin bottom text indent font size font family time roman right first negotiation biogen idec will have from receipt sale notice determine whether wish enter into negotiation with nbsp case change control purchase such controlling interest nbsp case program sale purchase applicable asset biogen idec notifies writing that would like enter into negotiation provided clause nbsp nbsp this section nbsp party will negotiate good faith period following date biogen idec written notice enter into definitive agreement negotiation period during first negotiation period will negotiate exclusively with biogen idec avoidance doubt negotiate with third party well remaining negotiation period party able enter into such agreement then party respective right obligation will forth such agreement nbsp biogen idec informs that wish enter into negotiation with provided clause nbsp nbsp this section nbsp nbsp biogen idec fails provide such notice that wish enter into negotiation with provided clause nbsp nbsp this section nbsp within required period nbsp biogen idec provides notice that wish enter into negotiation with provided clause nbsp nbsp this section nbsp within required period party fail style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman come agreement such agreement within negotiation period each case will have further obligation biogen idec with regard such change control program sale except that enter into program sale term that materially favorable aggregate than those offered biogen idec final offer period following negotiation period additionally nbsp able enter into definitive agreement with third party regarding program sale that meet requirement this section nbsp within period following negotiation period then biogen idec right under this section nbsp will reset with respect program sale will required provide sale notice regarding subsequent proposed program sale nbsp able enter into definitive agreement with third party regarding change control that meet requirement this section nbsp within period following negotiation period then biogen idec right under this section nbsp will reset with respect change control will required provide sale notice regarding subsequent proposed change control avoidance doubt paragraph nbsp nbsp this section nbsp will terminate further force effect following first occur nbsp program sale with third party that consummated accordance with term condition this section nbsp nbsp change control with third party that consummated accordance with term condition this section nbsp additionally paragraph nbsp nbsp this section nbsp will terminate with respect change control program sale upon consummation nbsp public offering common stock nbsp other transaction series transaction which entity with which merges becomes public reporting company wholly owned subsidiary public reporting company pursuant security exchange amended becomes listed company exchange wholly owned subsidiary listed company exchange each case excluding transaction that change control which addressed preceding sentence style margin margin bottom text indent font size font family time roman agreement agreement entered into connection with program sale change control will subject must consistent with term this agreement including limited term contained section will deliver biogen idec written notice program sale agreement together with copy executed agreement relating program sale later than following consummation such program sale redact from copy such agreement provided biogen idec hereunder term that applicable determination whether such agreement meet requirement this section nbsp style margin margin bottom text indent font size font family time roman dispute except extent resolution dispute claim between party otherwise addressed this agreement event dispute claim arising from this agreement term hereof including alleged breach such term either party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman written notice other party refer such dispute claim party respective officer designated below attempted resolution style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign nbsp biogen nbsp idec valign bottom valign bottom president other officer level individual designated biogen idec such purpose style font size height height colspan style font family time roman font size valign valign bottom valign bottom president other officer level individual designated such purpose table style margin margin bottom font size font family time roman such resolution reached within date referral foregoing officer then each party exercise right available under equity style margin margin bottom text indent font size font family time roman notice notice report required permitted given made under this agreement either party other will writing delivered other party address indicated below such other address addressee will have theretofore furnished writing addressor hand courier registered certified airmail postage prepaid style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign nbsp nbsp biogen nbsp idec valign bottom valign bottom biogen idec venture style font family time roman font size valign valign bottom valign bottom cambridge center style font family time roman font size valign valign bottom valign bottom cambridge style font family time roman font size valign valign bottom valign bottom attention nbsp nbsp nbsp nbsp executive vice president general counsel style font size height height colspan style font family time roman font size valign valign bottom valign bottom proteostasis therapeutic style font family time roman font size valign valign bottom valign bottom technology square fourth floor style font family time roman font size valign valign bottom valign bottom cambridge style font family time roman font size valign valign bottom valign bottom attention nbsp nbsp nbsp nbsp chief executive officer style font size height height colspan style font family time roman font size valign with copy valign bottom valign bottom edward wildman palmer style font family time roman font size valign valign bottom valign bottom huntington avenue style font family time roman font size valign valign bottom valign bottom boston style font family time roman font size valign valign bottom valign bottom attention nbsp nbsp joshua thayer table style margin margin bottom text indent font size font family time roman notice will effective date received addressee style margin margin bottom text indent font size font family time roman solicitation certain individual each party agrees that during term will directly indirectly solicit employ engage independent contractor then current employee other party affiliate been directly substantially involved research program notwithstanding above following solicitation will prohibited nbsp solicitation independent contractor either party their affiliate long they specifically directed either party solicit such individual nbsp solicitation style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman initiated through general newspaper advertisement other general circulation material directly targeted such individual nbsp solicitation such individual have first contacted either party their initiative directly through third party recruiter regarding employment engagement independent contractor style margin margin bottom text indent font size font family time roman governing this agreement will governed construed accordance with commonwealth massachusetts without taking into consideration choice principle that would lead application another jurisdiction style margin margin bottom text indent font size font family time roman binding effect this agreement will binding upon inure benefit party their respective legal representative successor permitted assigns style margin margin bottom text indent font size font family time roman heading section subsection heading inserted convenience reference only form part this agreement style margin margin bottom text indent font size font family time roman counterpart this agreement executed simultaneously more counterpart each which will deemed original both which together will constitute single agreement style margin margin bottom text indent font size font family time roman amendment waiver this agreement amended modified superseded canceled term this agreement waived only written instrument executed each party case waiver party party waiving compliance delay failure either party time time require performance provision will manner affect right later time enforce same waiver either party condition breach term contained this agreement whether conduct otherwise more instance will deemed considered further continuing waiver such condition breach such term other term this agreement style margin margin bottom text indent font size font family time roman purpose scope party hereto understand agree that this collaboration limited activity right obligation forth this agreement nothing this agreement will construed nbsp create imply general partnership between party nbsp make either party agent other purpose nbsp alter amend supersede vitiate other arrangement between party with respect subject matter covered hereunder nbsp give either party right bind other nbsp create duty obligation between party except expressly forth herein nbsp grant direct implied license other right other than expressly forth herein style margin margin bottom text indent font size font family time roman treatment collaboration without affecting section nbsp above party agree that exercise development option with respect style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman development compound party will thereafter treat collaboration partnership with respect such development compound accordance with partnership agreement between party that includes term forth exhibit style margin margin bottom text indent font size font family time roman assignment successor neither this agreement obligation party hereunder assigned either party including operation without consent other party biogen idec case consent harvard which consent will unreasonably withheld other party except that each party assign this agreement right obligation interest such party without consent other party without consent harvard case biogen idec nbsp whole part affiliate nbsp whole part purchaser substantially asset substantially asset which this agreement relates share representing majority common stock voting right successor corporation resulting from merger consolidation share exchange other similar transaction provided that assigning party shall deliver written notice such permitted assignment other party assignee shall agree writing bound term condition this agreement including obligation assigning party hereunder style margin margin bottom text indent font size font family time roman force majeure neither biogen idec will liable failure delay performing obligation forth this agreement neither will deemed breach obligation such failure delay force majeure event such force majeure party affected will reasonable effort avoid remove such cause nonperformance will continue perform hereunder with reasonable dispatch whenever such cause removed either party shall provide other party with prompt written notice delay failure perform that occurs reason force majeure party shall mutually seek resolution delay failure perform noted above style margin margin bottom text indent font size font family time roman interpretation party acknowledge agree that nbsp each party counsel reviewed negotiated term provision this agreement have contributed revision nbsp rule construction effect that ambiguity resolved against drafting party will employed interpretation this agreement nbsp term provision this agreement will construed fairly each party favor against either party regardless which party generally responsible preparation this agreement addition unless context otherwise requires wherever used singular will include plural plural singular gender will applicable gender word used inclusive sense word including used without limitation mean including without limitation style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman integration this agreement forth entire agreement with respect subject matter hereof thereof supersedes other agreement understanding between party with respect such subject matter style margin margin bottom text indent font size font family time roman severability should more provision this agreement become invalid party hereto shall substitute mutual consent valid provision such invalid provision which valid provision their economic effect sufficiently similar invalid provision that reasonably assumed that party would have entered into this agreement with such valid provision case such valid provision agreed upon invalidity several provision this agreement shall affect validity this agreement whole unless invalid provision such essential importance this agreement that reasonably assumed that party would have entered into this agreement without invalid provision style margin margin bottom text indent font size font family time roman further assurance each biogen idec each agrees duly execute deliver cause duly executed delivered such further instrument cause done such further thing including without limitation filing such additional assignment agreement document instrument other party time from time time reasonably request connection with this agreement carry more effectively provision purpose better assure confirm unto such other party right remedy under this agreement style margin margin bottom text indent font size font family time roman appointment committee member notwithstanding anything contrary forth herein appointment member including subcommittee project team each committee right each party obligation shall deliverable defined eitf issue each party shall free determine appoint member committee time during term reason either party shall have right withdraw from participation committee upon written notice other party which notice shall effective immediately upon receipt party appointing party appoint member committee withdraws from committee shall breach this agreement shall there associated penalty shall there impact consideration otherwise provided appointing party under this agreement unless until such person again appointed nbsp other party without regard provision herein with respect voting quorum dispute resolution discharge role committee which appointment were made with respect which withdrawal removal occurred appointing party nbsp appointing party shall participate meeting such committee time following effective date party appointed withdrawn from committee such party wish resume participating such committee such party shall notify other party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman writing thereafter such notifying party designees shall entitled attend subsequent meeting such committee participate activity decision making such committee failure appoint submission withdrawal notice occurred style margin margin bottom text indent font size font family time roman joint research agreement this agreement shall deemed joint research agreement within meaning section nbsp united state patent style margin margin bottom margin right text indent font size font family time roman third party beneficiary harvard intended third party beneficiary provision nbsp section nbsp with respect provision summary report only with respect provision summary report only except expressly stated immediately preceding sentence person entity other than biogen idec their respective affiliate permitted sublicensees assignee hereunder shall deemed intended beneficiary hereunder have right enforce obligation this agreement style margin margin bottom text indent font size font family time roman performance affiliate extent that this agreement imposes obligation affiliate party such party agrees cause affiliate perform such obligation either party more affiliate perform obligation duty hereunder affiliate party expressly granted certain right herein provided that each such affiliate shall bound corresponding obligation such party each party shall remain liable hereunder prompt payment performance respective obligation hereunder style margin margin bottom font size font family time roman align center remainder page left blank intentionally style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman witness whereof party have caused this agreement executed their duly authorized representative style font size margin margin bottom nbsp align right table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width style font family time roman font size valign colspan proteostasis therapeutic style font size height height colspan style font family time roman font size valign valign bottom valign bottom style margin margin bottom border bottom solid font size font family time roman david weiner style font family time roman font size valign name valign bottom valign bottom david weiner style font family time roman font size valign title valign bottom valign bottom interim style font size height colspan style font family time roman font size valign colspan biogen idec venture style font size height height colspan style font family time roman font size valign valign bottom valign bottom style margin margin bottom border bottom solid font size font family time roman steven holtzman style font family time roman font size valign name valign bottom valign bottom steven holtzman style font family time roman font size valign title valign bottom valign bottom executive vice president style font family time roman font size valign valign bottom valign bottom corporate development table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center initial research plan style margin margin bottom font size font family time roman align center style margin margin bottom font size nbsp style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center lead compound criterion style margin margin bottom font size font family time roman compound that style margin margin bottom font size nbsp style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center development compound criterion style margin margin bottom font size font family time roman lead compound that exhibit minimum criterion table below style margin margin bottom font size font family time roman align center style margin margin bottom font size font family time roman mutual agreement party update metric listed above with additional objective criterion research plan progress style margin margin bottom font size nbsp style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center third party agreement style margin margin bottom font size font family time roman amended restated license agreement between harvard dated december nbsp style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center calculation profit share style margin margin bottom font size font family time roman align center financial planning accounting reporting procedure style margin margin bottom text indent font size font family time roman this exhibit nbsp forth principle reporting actual result budgeted plan territory frequency reporting single functional currency provided section nbsp this agreement method determining payment party auditing account other matter related development compound developed licensed product under this agreement each developed product purpose this exhibit style margin margin bottom text indent font size font family time roman this exhibit nbsp provides agreed upon definition financial term applicable party purpose this agreement capitalized term used herein without definition shall have meaning ascribed thereto this agreement where applicable further definition contained herein reference this exhibit nbsp party party shall construed mean biogen idec proteostasis case every case shall deemed include party affiliate under this agreement style margin margin bottom text indent font size font family time roman notwithstanding anything this agreement contrary cost expense amount allocable chargeable party activity under this agreement shall allocated charged more than once unless otherwise specifically authorized party this agreement cost expense amount charged allocated party other party under this agreement shall chargeable allocable unless they nbsp directly related this agreement activity performed under this agreement nbsp calculated based internal cost accounting methodology charging allocating party consistently applied such party other program nbsp reasonable customary with respect global biopharmaceutical industry considering respective size activity party external cost expense amount allocated charged either party shall allocated charged only when they actually become payable upon receipt applicable bill invoice from third party style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign definition table style margin margin bottom text indent font size font family time roman developed product revenue mean revenue received party developed product other than sale right developed product under agreement with respect developed product other than sale style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman including limited monies received from third party pursuant license sublicense such upfront milestone royalty monies received from third party marketing right distribution right expressly understood that product revenue include monies paid party nbsp future research development extent that such monies actually expended such party such research development payment fair market value security such party nbsp result program sale change control assignment either party pursuant section nbsp this agreement other similar license sale transfer such party right such developed product style margin margin bottom text indent font size font family time roman collaboration budget mean written budget prepared party approved applicable accordance with section nbsp this exhibit shall include with respect each developed product revenue expense further defined herein incurred biogen idec proteostasis necessary support development commercialization such developed product collaboration budget shall include collaboration budget update shall constitute budget development plan discussed section nbsp this agreement budget commercialization plan discussed section nbsp this agreement style margin margin bottom text indent font size font family time roman collaboration operating profit mean profit positive loss negative resulting from commercialization developed product territory shall equal sale developed product territory plus developed product revenue territory operating expense style margin margin bottom text indent font size font family time roman cost clinical supply mean party cost produce acquire developed product clinical study which will determined accordance with gaap including without limitation nbsp labor material cost scrap cost waste cost defect cost cost rectify contamination cost obsolete inventory write offs label nbsp packaging cost each case extent directly consumed manufacture product quality assurance control storage shipping developed product nbsp allocable facility cost sewer water property allocable depreciation amortization cost facility equipment insurance other cost borne party that directly related manufacture product quality assurance control storage shipping commercial supply developed product this definition cost clinical supply shall style margin margin bottom text indent font size font family time roman cost good manufactured sale cogm mean party cost produce acquire commercial supply developed product which will determined accordance with gaap including without limitation nbsp labor material cost including charged biogen idec partnership manufacture material scrap cost waste style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman cost defect cost cost rectify contamination cost obsolete inventory write offs label nbsp packaging cost each case extent directly consumed manufacture product quality assurance control storage shipping developed product nbsp allocable facility cost sewer water property idle capacity cost only consistent with gaap such idle capacity been originally reserved manufacture such developed product within next twenty four nbsp month with express approval applicable allocable depreciation amortization cost facility equipment insurance other cost borne party that directly related manufacture product quality assurance control storage shipping commercial supply developed product this definition cogm shall exclude idle manufacturing cost biogen idec manufacturing plant that underutilized shall include third party cost incurred connection with manufacture developed product contract manufacturer extent that biogen idec burdened such cost style margin margin bottom text indent font size font family time roman cost sale mean developed product cost good manufactured sale third party royalty including royalty payable proteostasis under harvard license allocable intellectual property acquisition licensing cost either party included cogm including royalty payable biogen idec proteostasis third party pursuant section nbsp this agreement transport custom duty clearance sale borne seller deducted from sale style margin margin bottom text indent font size font family time roman development expense mean with respect developed product cost other direct cost expense directly related development activity such developed product that actually incurred biogen idec proteostasis their affiliate from date that proteostasis exercise development option through later nbsp date last regulatory approval obtained including thereafter cost maintain expand such regulatory approval territory each developed product nbsp date termination development final indication each developed product which regulatory approval sought territory such cost expense extent directly related development activity developed product shall include style margin margin bottom text indent font size font family time roman cost required obtain maintain expand authorization ability manufacture formulate fill ship sell developed product commercial quantity third party territory including cost party associated with transfer implementation manufacturing technology necessary qualify manufacturing facility style margin margin bottom text indent font size font family time roman cost development including cost study toxicological pharmacological metabolical clinical aspect developed product conducted internally individual investigator consultant necessary purpose obtaining style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman maintaining expanding marketing approval developed product process development process improvement scale cost validation cost including qualification cost clinical supply cost preparing submitting reviewing developing data information purpose submission governmental authority obtain maintain expand manufacturing marketing approval developed product cost phase clinical trial related developed product style margin margin bottom text indent font size font family time roman expense data management statistical design study document preparation other administration expense associated with clinical testing program style margin margin bottom text indent font size font family time roman cost clinical supply style margin margin bottom text indent font size font family time roman determining development expense chargeable under this agreement each party will respective project accounting system will review respective project accounting system methodology with other party party shall agree upon consistently apply methodology calculating allocating development expense based their respective internal accounting system party hereby agree that effort employee party affiliate performing activity hereunder shall charged development expense rate defined below notwithstanding anything this section contrary only those development expense that contemplated development plan collaboration budget were otherwise approved applicable shall chargeable party development expense payment made party third party connection with performance activity under development plan collaboration budget shall charged development expense such party actual pocket cost except extent included cost clinical supply expense incurred each party equipment material supply utilized performing activity under development plan collaboration budget shall separately charged development expense except those expense incurred party with prior written consent applicable forth development plan collaboration budget provided however that expense purchase making equipment material supply other than common laboratory supply pipette test tube petri dish reagent like that used exclusively connection with performance such party activity under development plan collaboration budget laboratory animal placebo supply shall charged development expense such party actual pocket expense incurred purchasing making such equipment material supply style margin margin bottom text indent font size font family time roman distribution cost mean cost other direct cost approved part collaboration budget specifically identifiable allocable distribution developed product commercial clinical including warehousing transportation order style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman entry custom duty insurance billing shipping credit collection other such activity approved applicable most recent full year forecast will include year date actual cost plus forecasted cost remaining portion such year clarity distribution cost shall include cost already included cost sale cost clinical supply cost deducted from sale purpose this definition cost that part distribution cost shall charged distribution rate described below final paragraph this exhibit style margin margin bottom text indent font size font family time roman marketing cost mean cost other direct cost actually incurred party connection with marketing promotion advertising developed product including without limitation cost preparing reproducing detailing developed product promotional material other promotional material cost professional education product related public relation relationship with opinion leader professional society market research market study before after product approval healthcare economics study other similar activity directly related developed product each case approved part commercialization plan collaboration budget marketing cost also include extent directly related development product actually incurred party approved part commercialization plan collaboration budget nbsp actual pocket cost outside service expense consultant agency meeting cost nbsp cost included exhibit term commercialization activity agreement including without limitation cost related customer facing activity plan nbsp activity related obtaining reimbursement from payer cost sale marketing data each case that previously included sale cost other cost definition herein purpose this definition cost that part marketing cost shall charged marketing rate described below final paragraph this exhibit marketing cost will specifically exclude cost activity which promote either party business whole without being specific development product such corporate image advertising style margin margin bottom text indent font size font family time roman medical education cost mean cost other direct cost designed ensure improve appropriate medical conduct medical education further research regarding developed product sold territory including example extent solely related development product contemplated commercialization plan development plan collaboration budget nbsp activity medical sale liaison nbsp grant support continuing medical education symposium third party research related developed product territory nbsp development publication dissemination publication relating developed product territory well medical information service provided response inquiry communicated sale representative received letter phone call email nbsp conducting advisory board meeting other consultant style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman program purpose which obtain advice feedback related development commercialization developed product territory purpose this definition cost that part medical education cost shall charged medical education rate described below final paragraph this exhibit style margin margin bottom text indent font size font family time roman sale definition forth section nbsp this agreement style margin margin bottom text indent font size font family time roman operating expense mean cost sale development expense marketing cost medical education cost sale cost other pocket cost distribution cost party agree that following cost shall considered operating expense unless expressly provided herein nbsp cost nbsp amortization depreciation expense nbsp deduction credit interest expense including without limitation extraordinary nonrecurring loss customarily deducted party calculating reporting consolidated income nbsp manufacturing facility capital cost capital expenditure including purchase facility property equipment unless such equipment exclusively used development commercialization developed product nbsp property other related development commercialization developed product style margin margin bottom text indent font size font family time roman other pocket cost mean other operating expense paid party their affiliate third party which part development expense considered approved applicable expense purpose cost sharing arrangement under this agreement other pocket cost shall limited following style margin margin bottom text indent font size font family time roman style margin margin bottom text indent font size font family time roman patent expense mean pocket expense reasonably incurred party prepare file prosecute maintain patent right biogen idec patent right joint patent right including cost interference opposition proceeding with respect such patent right addition patent expense shall include cost freedom operate search analysis with respect developed product extent such search analysis have been authorized patent coordinator style margin margin bottom text indent font size font family time roman sale cost shall mean cost other direct cost specifically identifiable sale developed product territory approved part commercialization plan collaboration budget sale cost shall include cost associated with sale representative such recruiting relocation compensation benefit travel training sale representative sale meeting detail sale call reporting work managed care account cost related customer service other sale customer service style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman related expense only extent deducted from sale included cost distribution cost marketing other component operating expense purpose this definition cost that part sale cost shall charged sale rate described below final paragraph this exhibit style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign collaboration budget quarterly update table style margin margin bottom text indent font size font family time roman first collaboration budget soon practical following exercise development option section nbsp this agreement biogen idec proteostasis will prepare collaboration budget development plan current calendar year which proteostasis exercised right soon reasonably possible specifying detail activity performed during year staffing level approved third party contractor style margin margin bottom text indent font size font family time roman yearly update biogen idec proteostasis shall annual basis prepare collaboration budget which shall specify detail applicable development commercialization activity performed during such year designation which party responsible each task staffing level which level shall reasonably necessary attainment development goal applicable approved third party contractor required carry such activity estimated expenditure required carry such activity timeline completion such activity annual production requirement each update collaboration budget under this paragraph modification quarterly collaboration budget update outlined below shall automatically deemed constitute amendment collaboration budget upon applicable approval ratification meeting minute related thereto shall constitute obligation either party until such approval ratification collaboration budget will contain monthly detail number collaboration budget will supplemented with high level business plan cost clinical trial registration application plan product introduction sale effort promotion style margin margin bottom text indent font size font family time roman quarterly collaboration budget update also referred quarterly forecast biogen idec proteostasis shall revise collaboration budget quarterly basis during course each year based nbsp review actual activity category contributing calculation collaboration operating profit nbsp determination necessary change collaboration operating profit associated category style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign reporting table style margin margin bottom text indent font size font family time roman reporting each party shall report other party quarterly forecast actual result operation presented following format developed product basis with category defined section nbsp this exhibit style margin margin bottom margin left font size font family time roman income statement style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign valign bottom nbsp valign bottom style margin margin bottom font size font family time roman sale style margin margin bottom font size font family time roman plus developed product revenue style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman cost sale excluding item deducted sale style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman gross profit style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman development expense style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman marketing cost style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman sale cost style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman medical education cost style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman other pocket cost style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman contribution style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman distribution cost style font family time roman font size valign valign bottom nbsp valign bottom style margin left text indent font size font family time roman collaboration operating profit loss table style margin margin bottom text indent font size font family time roman intention party that interpretation these definition will accordance with gaap style margin margin bottom text indent font size font family time roman reporting each party will performed follows style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman reporting event valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center frequency valign bottom nbsp nbsp valign bottom align center style border bottom solid style margin margin bottom font size font family time roman align center timing submission style font family time roman font size valign actuals valign bottom nbsp nbsp valign align center monthly valign bottom nbsp nbsp valign after month style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman quarterly collab budget update remaining calendar year valign bottom nbsp nbsp valign align center quarterly valign bottom nbsp nbsp valign following calendar quarter applicable approved date style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman preliminary collab budget year month valign bottom nbsp nbsp valign align center annually valign bottom nbsp nbsp valign applicable approved date style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman final collab budget year month valign bottom nbsp nbsp valign align center annually valign bottom nbsp nbsp valign applicable approved date table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman financial representative from party will review financial information meet appropriate shall event meet person least quarterly review approve following style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign actual result table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign quarterly forecast table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign collaboration budget table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign inventory level table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left width valign nbsp align left valign sale return allowance table style margin margin bottom text indent font size font family time roman reconciliation statement within following calendar quarter each party shall submit other party reconciliation report encompassing actual result first month such quarter preliminary actual result third month within following calendar quarter each party shall submit other party report actual result outlined above expense charged either party shall exceed amount included total expenditure then current collaboration budget unless other party approves such excess expense actual cost party implementing activity such party under collaboration budget expected vary more than from amount budgeted expenditure during calendar year such party will promptly revise collaboration budget submit writing with explanation variance reason therefor approval applicable applicable approve variance amount which actual cost exceed budgeted cost collaboration budget shall borne party that incurred cost style margin margin bottom text indent font size font family time roman financial representative from each party shall responsible following calendar quarter preparing statement reconciliation statement format agreed party showing each party full quarter actual result calculation sale developed product revenue cogm cost sale development expense marketing cost medical education cost sale cost distribution cost other pocket cost reconciliation statement report actual result compared collaboration budget will sent each party within following calendar quarter approval each party shall provide notice approval rejection reconciliation statement within receipt both party approve reconciliation statement will sent applicable information either party reject reconciliation statement within after receipt applicable shall meet approve otherwise resolve reconciliation statement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman approved reconciliation statement show that party incurred more than share cost expense applicable calendar quarter provided collaboration budget such party will promptly upon approval reconciliation statement submit other party invoice difference between actual cost expense such calendar quarter share collaboration budget which will paid receiving party within after receipt such invoice style margin margin bottom text indent font size font family time roman development expense reporting after phase development termination option exercised proteostasis exercise phase development termination option pursuant section nbsp this agreement proteostasis shall provide biogen idec final report development expense collaboration compound within after calendar quarter which such phase development termination option take effect style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign audit interim review section nbsp this agreement table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign methodology table style margin margin bottom margin left font size font family time roman tracking cost style margin margin bottom text indent font size font family time roman each party shall report operating expense based project cost system which shall event track ftes functional area month using such other system such party applies with respect internal program general these project cost system shall report actual allocable time spent specific project apply appropriate rate capture actual allocable cost specific project allocate other expense project ftes that charge time project included definition operating expense shall included style margin margin bottom text indent font size font family time roman total budgeted expense incorporated rate shall include style margin margin bottom text indent font size font family time roman cost rate shall apply cost related development expense ongoing development expense developed compound rate will initially rate date proteostasis exercise development option will increase annually provided section nbsp this agreement style margin margin bottom text indent font size font family time roman sale marketing distribution medical education cost cost related sale cost marketing cost distribution cost medical education cost will part annual budgeting process will calculated using current year most recent full year forecast provided that initial year which such cost expected incurred such cost will calculated mutual agreement party based comparable activity compensation similarly situated company biotechnology industry most recent full year forecast will include style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center term commercialization activity agreement style margin margin bottom font size font family time roman commercialization agreement negotiated party pursuant section nbsp agreement commercialization activity agreement will contain term substantially similar following material term capitalized term used this exhibit otherwise defined have meaning given them main body collaborative research development license agreement license agreement style margin margin bottom text indent font size font family time roman customer facing activity style margin margin bottom text indent font size font family time roman biogen idec acknowledge agree that overall objective customer facing activity defined below relating licensed product united state reach optimal customer audience that will maximize brand value within each indication that subject regulatory approval with reasonable return investment biogen idec will prepare consultation with customer facing activity plan defined below united state which will include strategy customer facing activity including limited nbsp sale force medical affair reimbursement account management activity number customer facing ftes defined below each party allocated thereto nbsp size structure incentive compensation training deployment customer target customer facing ftes style margin margin bottom text indent font size font family time roman will review approve customer facing activity plan each indication united state avoidance doubt will have final decision making right regarding content development execution customer facing activity plan including limited following aspect customer facing activity plan style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign commercial model footprint united state including limited appointment management distribution channel table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign development deployment patient service activity applicable table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign determination number customer facing ftes each function including medical affair sale other function defined customer facing activity plan table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign development modification roll training material used training party customer facing ftes table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign establishment parameter performance sale goal incentive compensation engagement operational metric number call target plan reimbursing product measurement business goal table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign relation communication with patient others inquiring about clinical study clinical licensed product after effective date commercialization activity agreement accordance with protocol mutually agreed upon party table style margin margin bottom text indent font size font family time roman biogen idec will responsible managing customer facing activity plan biogen idec will responsible executing customer facing activity plan biogen idec will update periodically execution performance each party customer facing ftes using agreed upon metric defined customer facing activity plan style margin margin bottom text indent font size font family time roman biogen idec will annually review whether customer facing ftes each party properly trained with respect licensed product indication that subject regulatory approval compliance with applicable addition style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign biogen idec will determine number customer facing ftes function well number supervisory ftes time first filing regulatory approval table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign will have opportunity provide customer facing ftes customer facing ftes unless higher number requested agreed biogen idec table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign biogen idec will have right reasonably determine qualification customer facing ftes which shall similar qualification biogen idec customer facing ftes assigned same similar task table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign will responsible hiring customer facing ftes supervisory ftes table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign customer facing ftes will report into supervisory ftes table style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign biogen idec will have sole control authority over training customer facing ftes table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width nbsp width valign align left align left valign biogen idec will have sole control authority over establishment standard performance customer facing ftes which will same standard performance biogen idec customer facing ftes customer facing ftes will adhere such standard performance will subject same disciplinary action including termination they were biogen idec customer facing ftes table style margin margin bottom text indent font size font family time roman commercialization effort each party will commercially reasonable effort execute obligation under customer facing activity plan accordance with license agreement style margin margin bottom text indent font size font family time roman recording commercialization activity employee representative will record commercialization related activity biogen idec customer relationship management system same manner following same rule biogen idec employee biogen idec will commercialization related data recorded biogen idec customer relationship management system provided that shall have access right such data customer facing activity license agreement terminated under section nbsp nbsp biogen idec under section nbsp then biogen idec will make customer relationship management system data available exclusive basis solely extent that such data specific terminated licensed product style margin margin bottom text indent font size font family time roman sale mechanism sale licensed product united state will booked biogen idec through biogen idec customer relationship management system during term commercialization activity agreement receives order from customer licensed product will refer such order biogen idec style margin margin bottom text indent font size font family time roman cost customer facing activity party will share cost customer facing activity supervisory ftes licensed product accordance with term calculation profit share exhibit license agreement provided however that style margin margin bottom text indent font size font family time roman cash incentive compensation structure customer facing ftes supervisory ftes relating commercialization licensed product will similar biogen idec cash incentive compensation structure similarly situated personnel biogen idec style margin margin bottom text indent font size font family time roman biogen idec will have obligation reimburse that portion cash salary benefit cost customer facing ftes supervisory ftes that excess biogen idec cash salary benefit compensation level biogen idec personnel performing same similar duty style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman neither party will have obligation reimburse other party that portion compensation paid such other party customer facing ftes supervisory ftes activity unrelated commercialization licensed product manner calculating reporting such allocation compensation each party shall reasonably determined such party subject approval other party such approval unreasonably withheld conditioned delayed style margin margin bottom text indent font size font family time roman notwithstanding subsection nbsp nbsp this section nbsp sole discretion provide stock equity based compensation structure customer facing ftes supervisory ftes extent whatever form desire style margin margin bottom text indent font size font family time roman training promotional material support biogen idec shall nbsp provide same product compliance training customer facing ftes biogen idec designated site provides customer facing nbsp provide promotional marketing material sample licensed product quantity sufficient support customer facing activity nbsp coordinate sale call with customer facing ftes include customer facing ftes licensed product call plan established biogen idec nbsp provide additional reasonable support forth commercialization activity agreement style margin margin bottom text indent font size font family time roman material breach material breach obligation under commercialization activity agreement fails cure such breach within sixty nbsp after receipt written notice from biogen idec then biogen idec terminate right continue participate commercialization activity united state with respect commercialized product affected such material breach commercialization activity agreement will contain dispute resolution mechanism that invoked party feel that breach obligation under commercialization activity agreement provision this section nbsp will limit right either party nbsp seek obtain other remedy available under commercialization activity agreement under license agreement equity such breach nbsp claim other material breach other party under commercialization activity agreement license agreement style margin margin bottom text indent font size font family time roman right withdraw from commercialization withdraw from continued participation commercialization activity united state with respect more commercialized product nbsp providing biogen idec with advanced written notice unless shorter time period mutually agreed party nbsp provided that such withdrawal shall contingent biogen idec agreement plan affect orderly withdrawal purpose clarity will responsible payment associated arising from such withdrawal associated with such withdrawal transition activity biogen idec style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom text indent font size font family time roman certain definition style margin margin bottom text indent font size font family time roman customer facing activity plan mean that part commercialization plan that deal with customer facing activity united state determines separate plan customer facing activity each licensed product united state approved including further approval within organization required pursuant internal protocol promotion pharmaceutical product consistently applied throughout organization style margin margin bottom text indent font size font family time roman customer facing activity mean with respect each licensed product contact representative within united state with medical professional with prescribing authority other individual entity that have significant impact influence prescribing decision including those entity that responsible payment reimbursement pricing effort inform such person about such licensed product approved within united state style margin margin bottom text indent font size font family time roman customer facing mean with respect party employed such party engaged customer facing activity united state style margin margin bottom text indent font size font family time roman supervisory mean with respect party employed such party engaged overseeing customer facing ftes united state style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center harvard development milestone style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign september nbsp licensee accomplished following with respect licensed product detail will provided annual report table style margin margin bottom text indent font size font family time roman style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign licensee will accomplish following with respect licensed product table style margin margin bottom text indent font size font family time roman style margin margin bottom font size nbsp style page break before always size style color width align center style margin margin bottom font size font family time roman certain confidential portion this exhibit were omitted replaced with complete version this exhibit been filed separately with secretary security exchange commission pursuant application requesting confidential treatment pursuant rule promulgated under security amended style margin margin bottom font size font family time roman align right execution version style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center exhibit style margin margin bottom font size font family time roman align center matter partnership term style font size margin margin bottom nbsp style line height margin margin bottom border bottom solid nbsp style margin margin bottom font size font family time roman align center summary term style margin margin bottom font size font family time roman align center regarding partnership agreement collaboration agreement style font size margin margin bottom nbsp center style line height margin margin bottom border bottom solid width nbsp center style margin margin bottom text indent font size font family time roman forth below summary term partnership agreement triggered exercise commercialization option pursuant collaboration agreement partnership agreement style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width style font family time roman font size valign style margin left text indent font size font family time roman nbsp nbsp nbsp nbsp nbsp nbsp partie valign bottom valign bottom style margin margin bottom margin left text indent font size font family time roman nbsp nbsp nbsp nbsp nbsp biogen biogen idec venture specified affiliate style font size margin margin bottom nbsp style margin margin bottom margin left text indent font size font family time roman nbsp nbsp nbsp nbsp nbsp proteostasis therapeutic specified affiliate table style margin margin bottom font size font family time roman align center style margin margin bottom font size nbsp body html text document